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ABSTRACT

Comparison of Chikungunya Virus Strains in Disease Severity and Susceptibility
to T-705 (Favipiravir), In vitro and In vivo

By

Makda S. Gebre, Master of Science
Utah State University, 2017

Major Professor: Dr. Justin Julander
Department: Animal, Dairy, and Veterinary Science

Chikungunya virus (CHIKV) is an arbovirus that typically causes painful
arthralgia, fever and rash in infected patients and is currently listed as a priority
pathogen by the National Institute of Allergy and Infectious Diseases (NIAID),
NIH. Various CHIKV strains have been classified into three phylogenetic groups
or clades, namely West African, Asian and East/Central/South African (ECSA).
Currently, there are no FDA approved therapeutics or vaccines used to treat or
prevent Chikungunya. In order to understand inter-strain differences in disease
phenotype and antiviral response, we compared two CHIKV strains from each
clade in cell culture and in mouse models.
There was a difference in replication kinetics between different CHIKV
strains. West African strains replicated more robustly and were slightly less
sensitive to treatment with the test antiviral, T-705. This was further supported by
studies in mice where West African strains, and similarly ECSA strains, caused a
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more severe disease phenotype and were less readily protected by T-705 as
compared with Asian lineage strains. These studies suggest there is a difference
in disease severity and response to antiviral treatment between CHIKV lineages.
(114 Pages)
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PUBLIC ABSTRACT

Comparison of Chikungunya Virus Strains in Disease Severity and Susceptibility
to T-705 (Favipiravir), In vitro and In vivo
Makda S. Gebre
Chikungunya is a mosquito-transmitted disease caused by Chikungunya
virus (CHIKV). Symptoms of Chikungunya include debilitating joint pain and
swelling, fever and rash. CHIKV was first discovered in 1953 in Tanzania, and
has since caused periodic outbreaks of disease. The virus reemerged recently in
2004 and has since spread around the world affecting more than 3 million
people. The different strains of CHIKV have been grouped into three
phylogenetic clades: West African, Asian and East/Central/South African
(ECSA). There are no FDA approved medicines or vaccines used to treat or
prevent CHIKV infection. The antiviral drug, T-705 (commercially known as
Favipiravir), has recently been shown to have activity against CHIKV. T-705 has
already been approved in Japan for the treatment of influenza and is currently
going through clinical trials in the US.
Since there may be phenotypic differences between the clades of CHIKV,
it is important to first characterize distinctions between the strains and determine
the susceptibility of these strains to treatment. To do this, we obtained two
different CHIKV strains from each of the three phylogenetic groups. These
CHIKV strains displayed differences in their ability to replicate in cell culture and
exhibited only slight differences in susceptibility to T-705 treatment. However,
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more profound differences were observed in mouse models where differences in
disease severity and response to T-705 treatment were observed.
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CHAPTER 1
INTRODUCTION

Chikungunya virus (CHIKV) is a mosquito-borne virus that causes
Chikungunya (CHIK). The key symptoms of CHIK include fever, rash and joint
pain that can last from weeks to several years. Other symptoms include joint
swelling, headache and muscle pain. Although CHIK has a low mortality rate
(one death occurring in 1,000 clinical cases), 50–97% of infected individuals
show clinical symptoms (Gerardin et al., 2008b). Chronic symptoms that persist
two years after initial infection have also been observed in 43–75% of CHIK
patients (Gerardin et al., 2011).
CHIKV was first identified in 1953 in Tanzania (Powers and Logue, 2007).
The word “Chikungunya” comes from the Makonde language spoken in southeast Tanzania and northern Mozambique. The word literally translates to mean
“that which bends up” referring to the bent posture of CHIK patients (Mohan et
al., 2010). CHIKV has caused several minor outbreaks in the decades following
its discovery. However, within the last decade it has extensively spread
throughout the world becoming a great public health concern.
In 2004, a virus strain emerged from the coast of Kenya to extensively
spread to numerous regions in Africa, South-east Asia and Europe affecting
millions of people (Graham et al., 2016). Between 2005-2007, CHIKV infected
300,000 people in the islands of the Indian ocean, 1.4 million people in India and
42,000 people in Thailand (Schwartz and Albert, 2010). A mutation that allowed
the virus to adapt a new vector further expanded the geographic range of
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infection of the virus to temperate areas (Tsetsarkin et al., 2007). In 2013, CHIKV
reached the Americas causing 1.1 million cases within a year (Yactayo et al.,
2016). The various strains of CHIKV currently present in different parts of the
world have been grouped into three phylogenetic groups or clades, namely, West
African, Asian and East/Central/South African (ECSA). The strains that emerged
recently in the Americas are classified within the Asian lineage, likely introduced
by an infected traveler.
Thus far, no approved antiviral therapies or vaccines exist for CHIKV.
However, a broad-spectrum viral RNA polymerase inhibitor, T-705 (Favipiravir)
has been identified as a prime candidate (Ahola et al., 2015).

1.1. Statement of the Problem
As CHIKV rapidly spreads around the world, it is critical to understand
similarities and differences in disease manifestation that occur due to infection
with different CHIKV lineages and to identify broad-spectrum vaccines and
antiviral drugs that can be implemented globally. We have previously been
working with two strains of CHIKV, S27 and LR2006_OPY1 (LR06), and have
demonstrated different levels of disease severity in a mouse model. Briefly, mice
infected with S27 or LR06 strains of CHIKV had significantly different levels of
footpad swelling at various times after infection (Fig. 1). In fact, infection with
10,000-fold less virus inoculum of LR06, as compared with S27 challenge,
resulted in a similar footpad swelling profile (Fig. 1).
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This led us to question if differences in disease phenotype and antiviral
response exist between strains from different virus clades. Thus far, no published
studies have been conducted to address this question. Therefore, this project is
primarily conducted to fill that knowledge gap.
In addition to S27 and LR06, which are grouped together in the ECSA
clade, we obtained British Virgin Islands (BVI) and Indonesia (IND) strains of the
Asian clade and Senegal (SEN) and Nigeria (NGR) strains that fall within the
West African clade. The BVI strain is of particular interest as it is an Asian strain
currently circulating in the Caribbean. The differences in disease phenotype
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Fig. 1. Percent change in footpad thickness between inoculated foot and
non-inoculated foot of DBA/1J mice infected with 108 CCID50 of S27 or 107.3
CCID50 and 103.3 CCID50 of LR06 of CHIKV. (****P<0.0001, **P<0.01, 107.3
CCID50 of LR06 compared to 108.0 CCID50 of S27; CCID50: 50% cell culture
infectious dose)
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observed in mice infected with S27 and LR06, which are within the same clade,
suggest that strain differences may not strictly be based on phylogenetic
grouping. As shown in the phylogenetic tree (Fig. 2), each clade is represented in
our study by two strains. Geographic distribution of the strains is shown in Figure
3 and information on their origins and history is provided in Table 1.

Fig. 2. Phylogenetic tree of strains of CHIKV used for in vitro and in vivo
strain comparison experiments. Evolutionary history was constructed with
MEGA7 software using complete genome sequences obtained from the
GenBank database. Maximum Likelihood method was used for analysis based
on Tamura-Nei model. The tree is drawn to scale, with branch lengths measured
in the number of substitutions per site. The percentage of bootstrap replicates
(1,000 bootstrap replications, confidence probability 100%) are indicated at the
nodes. The analysis included CHIKV strains from British Virgin Islands (BVI,
KJ451624.1, 2013), Indonesia (IND, HM045797.1, 1985), La Reunion (LR06,
DQ443544.2, 2006), Tanzania (S27, AF369024.2, 1953), Senegal (SEN,
AY726732.1, 1983) and Nigeria (NGR, HM045786.1, 1964). Ross River Virus
(RRV, NC_001544.1, 2012), a closely related alphavirus that also belongs in the
Semliki Forest virus complex, was introduced to add correct rooting of tree.
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Fig. 3. Geographic distribution of strains from three phylogenetic groups of
CHIKV.

Table 1
History and origins of BVI, IND, SEN, NGR, S27 and LR06 CHIKV strains used
for in vitro and in vivo comparison.
Clade
Abbreviation
Strain ID
Country of origin
Collection Date
Source
Serogroup
Passage history

Asian
BVI
IND
R 99659
RSU 1
British Virgin
Indonesia
Island

ECSA

West African
SEN
NGR
37997
IB H 35

S27
S27

LR06
LR2006_OPY1

Tanzania

La Reunion

Senegal

Nigeria

2006

1983

1964

Mosquito
(Aedes)
A

Human
(Serum)
A

Vero 3

Vero 1

2013

1985

1953

Human
(Serum)
A

Human
(Serum)
A

Human
(Serum)
A

Vero 2

Vero 2

C6/36

Human
(Serum)
A
Vero E6
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Hypothesis: Based on our preliminary data we hypothesized that CHIKV strains
differed in disease phenotype and response to antiviral treatment.
Specific aims:
1. Compare different CHIKV strains in replication kinetics and susceptibility to T705 in cell culture.
1.1. Conduct growth curve experiment to determine infectivity and replication
kinetics of CHIKV strains in various cell lines.
1.2. Compare conversion of T-705-RTP in these cell lines to identify suitable
cell lines to test antiviral activity.
1.3. Test antiviral activity of T-705 against different strains of CHIKV
belonging to the 3 phylogenetic clades.
2. Determine differences between CHIKV strains in disease severity and
susceptibility to T-705 in vivo in arthralgia and lethal mouse models.
2.1. Characterize CHIKV strains in DBA/1J (arthralgia model) and AG129
(lethal model) mice to determine disease phenotype and severity.
2.2. Examine antiviral activity of T-705 against CHIKV strains in both models.
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CHAPTER 2
LITERATURE REVIEW

2.1. Molecular Biology of CHIKV
As a member of the Alphavirus genus in the Togaviridae family, CHIKV
contains a linear positive-sense, single-stranded RNA genome with a size of
about 11.6 kb (Powers and Logue, 2007). In neutral pH, the diameter of CHIKV
measures around 70nm (Lum and Ng, 2015). The virus is unstable above 58°C.
The genome of CHIKV contains a 5’ methylated terminal cap and a 3’
terminal poly-A tail. It encodes 4 non-structural proteins (nsP1-4) and 5 structural
proteins (6K, C and E1-3). Together, the four non-structural proteins form the
replication complex. nsP1 is involved in the initiation of the negative strand RNA
synthesis. It also participates in the methylation and capping of positive RNA
strands (Schwartz and Albert, 2010).

Fig. 4. Structural organization of the single-strand RNA genome of CHIKV.
The junction region (J) is a non-coding joining gene segment. (nsP = nonstructural protein; E = Envelope; aa= amino acids)
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nsP2 functions as an RNA helicase, but also has triphosphatase and
proteinase activities. It shuts off host cell transcription. nsP3 is a replicase unit,
while nsP4 functions as an RNA-dependent RNA polymerase enzyme (Lum and
Ng, 2015). The 6K protein is involved in virus assembly (Leung et al., 2011). The
capsid protein forms the icosahedral nucleocapsid of CHIKV along with 80
trimeric spikes. A trimeric spike is composed of three heterodimers, each
containing both E1 and E2 proteins. The E3 protein interacts with the E2
glycoprotein, and directs other structural proteins towards the ER of the cell for
assembly (Snyder and Mukhopadhyay, 2012). It is also involved in the budding
out of CHIKV (Uchime et al., 2013).
According to Bernard et al (2010), CHIKV enters the cell through an
Eps15-dependent, clathrin-independent endocytosis. Successful infection
requires a Rab5-positive endosomal compartment (Bernard et al., 2010).
Although neither mosquito nor human cell receptors for CHIKV entry have been
identified, C-type lectins and heparin sulfate proteoglycans are believed to be
involved (Leung et al., 2011).
Once in the cellular endosome, low pH environment activates
conformational changes in the E1 glycoprotein which allows fusion of the CHIKV
membrane with the endosomal membrane (Lum and Ng, 2015). This results in
the release of the nucleocapsid into the cytoplasm of the cell. Free viral genome
is then translated by the cellular machinery into a replication complex that
eventually generates a full-length negative sense RNA intermediate. The
negative sense RNA intermediate is transcribed by the replication complex into
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subgenomic (26S) and genomic (49S) positive sense viral RNA. The 26S
subgenomic mRNA is translated into the structural proteins: C(Capsid), 6K, E1
and pE2. pE2 is further cleaved into E2 and E3 glycoproteins in the cellular
Golgi-apparatus. The capsid protein auto-assembles into an icosahedral
nucleocapsid incorporating the 49S viral genome in the cytoplasm. Near the
plasma membrane of the cell, glycoproteins E1 and E2 hetrodimerize and are
incorporated onto the nucleocapsid as trimeric spikes to form a complete virion.
As the newly mature virion buds out, it adds on a double membrane from the
host cell membrane (Lum and Ng, 2015). Although the exact budding mechanism
is not completely understood, it is known to require the binding of the
nucleocapsid with E2 proteins present on the cell membrane (Solignat et al.,
2009).

2.2. Pathogenesis of CHIKV
When CHIKV first infects a human host through a mosquito bite, it invades
dermal fibroblasts and macrophages where initial rounds of replication occur
(Kam et al., 2009). Peripheral blood mononuclear cells (PBMCs) such as Natural
killer cells, B cells and T cells are also susceptible (Sourisseau et al., 2007).
From the site of infection, the virus enters the lymphatic system and
consequently, the blood where it disseminates to peripheral tissues/organs such
as the spleen, liver, brain, muscles and joints (Lum and Ng, 2015).
CHIKV replicates in various types of cells, including epithelial, endothelial
and fibroblast cells (Sourisseau et al., 2007). The virus uses Macrophages as
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reservoirs to continue to manifest symptoms chronically (Wintachai et al., 2012).
Ross River virus, a closely related alphavirus within the Semliki Forest virus
complex (Powers et al., 2001), was found to persist in synovial Macrophages 10
months after disease onset in chronically ill patients (Hoarau et al., 2010). It is
believed that Chikungunya has a similar persistence in Macrophages localized in
joints (Lum and Ng, 2015).
After 2-10 days post-infection, viremia is cleared in human patients. This is
primarily due to the type I interferon (IFN) pathway of the innate immune system
(Gardner et al., 2010). The pathway is initiated when pattern recognition
receptors (PRRs) such as Toll-like receptors, RIG-I-like receptors (MDA5) and
RIG-I, recognize pathogen-associated molecular patterns (PAMPS) including
double-stranded RNA formed during replication of CHIKV in the cytoplasm of the
cell (Stetson and Medzhitov, 2006). After recognition, downstream signaling
cascades involving Caspase Recruitment Domain (CARD) adaptor, IFNβ adapter
protein (CARDIF) and crucial interferon-regulatory factors (IRF-3 and IRF-7)
collectively result in type I IFN production (Stetson and Medzhitov, 2006).
Through JAK-STAT signaling, IFNs induce the expression of a multitude of
genes called interferon-simulated genes (ISGs), including inflammatory cytokines
and chemokines resulting in an anti-viral state within the infected host (van
Boxel-Dezaire et al., 2006).
ISGs including Viperin, Mx proteins, protein kinase R (PKR) and 2’, -5’oligoadenylate synthase 3 (OAS3) have anti-viral properties (Brehin et al., 2009;
Lum and Ng, 2015; Schoggins and Rice, 2011; Werneke et al., 2011). For
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example, OAS3 activates RNase L, which is a latent nuclease that degrades viral
RNA (Lohofener et al., 2015).
In addition to IFNs α/β/γ, other cytokines elevated in patients experiencing
acute CHIKV infection include IL-2, IL-2R, IL-6, IL-7, IL-12, IL-5 IL17 and IL-17.
Chemokines such as granulocyte colony-stimulating factor (GM-CSF), monocyte
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP) and
fibroblast growth factor (FGF) have also been shown to have been elevated
during CHIKV infection (Teng et al., 2015).
The adaptive immune system plays an important role in the control and
elimination of CHIKV. CD4+ T cells were found to be significantly elevated in the
spleen and feet of mice infected with CHIKV (Teo et al., 2013). CHIKV specific
CD4+ T cells have been found to be critical in mediating joint swelling and
inflammation in mice in the absence of IFN-γ (Teo et al., 2013). The function of
CD8+ T cells in the immune response to CHIKV infection still remains to be
examined. In mice, regulatory T cells (Tregs) have been shown to ameliorate
CHIKV induced pathology by driving activated T cells into anergy (Lee et al.,
2015).
B cells participate in limiting CHIKV virus replication by producing antiCHIKV immunoglobulins (Igs). In mice lacking B cells, viremia has been shown to
persist over a year, underlining the importance of B cells in CHIKV clearance
(Lum et al., 2013). The primary target of anti-CHIKV antibodies is the E2
glycoprotein. In a study conducted by Kam et al (2015), 72-100% of CHIK
patients have anti-CHIKV antibodies that recognized the E2EP3 epitope on the
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E2 glycoprotein (Kam et al., 2015). The E2EP3 peptide is conserved across
various CHIKV strains, and has successfully been used in a pre-clinical
vaccination study where it significantly reduced joint pathology in mice (Kam et
al., 2012).

2.3. Clinical Symptoms of CHIK
CHIKV is one of 30 viruses that belong to the genus Alphavirus.
Alphaviruses are divided into New World and Old World viruses. New World
alphaviruses cause encephalitis while infection with Old World alphaviruses
primarily results in polyarthritis and rash (Schwartz and Albert 2010). Although
CHIKV is classified as an Old World virus and primarily causes the symptoms
typical of this group, it has also been documented to cause meningoencephalitis
in rare instances (Gerardin et al., 2008b). In these cases, CHIKV infects stromal
cells lining the choroid plexus rather than directly infecting neurons of the central
nervous system.
When first isolated in Tanzania, symptoms of CHIKV were considered
indistinguishable from Dengue (Robinson, 1955). Currently, the disease is
primarily diagnosed through viral RNA or antibody in patient samples. Symptoms
of CHIK set in 2-4 days post-infection and include fever (92%), arthralgia (87%),
backache (67%), headache (62%) and maculopapular rash (50%) (WHO, 2008).
Infrequent symptoms include stomatitis (25%) and oral ulcers (10%) (WHO,
2008). Symptoms are observed 4-7 days-post infection (Lum and Ng, 2015).
Viremia persists 5 days after symptoms begin. Although arthralgia could persist
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for years, most of the symptoms disappear within a week (Kam et al., 2009).
Other symptoms such as myeloradiculopathy and meningoencephalitis have also
been associated with CHIKV (Chandak et al., 2009). Rarely, meningeal
syndrome, vomiting and diarrhea are observed in CHIK patients.
Although CHIK has a very low mortality rate (one death occurring in 1,000
clinical cases), infected individuals have a morbidity rate between 45-97%
(Rezza et al., 2007). Specifically, polyarthralgia is observed in 87-98% of patients
(Thiberville et al., 2013). Chronic symptoms that persist two years after initial
infection are observed in 43 – 75% of CHIK patients (Gerardin et al., 2011).

2.4. Transmission of CHIKV
Chikungunya virus is an arbovirus transmitted by female mosquitoes. The
virus has two transmission cycles, sylvatic and urban. In Africa, the virus
circulates primarily in the sylvatic cycle infecting wild primates, birds, rodents and
squirrels. It is transmitted through Aedes mosquitoes including A. africanus, A.
furcifer-taylori, and A. dalzieli. In the urban cycle, which is primarily prevalent in
Asia, the virus is transmitted between humans through A. aegypti and A.
albopictus (Thiboutot et al., 2010).
All age groups are susceptible to CHIKV. There is no evidence of
transmission of CHIKV through breastfeeding or sexual contact. Transplacental
transmission of CHIKV does not likely occur (Chen et al., 2010). In extremely
rare conditions, the virus is transmitted from mother to newborn during the
perinatal period through exposure during parturition. In a multidisciplinary study
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conducted by Gerardin et al., vertical CHIKV transmission was investigated in
7,504 pregnant women and 7,629 neonates. Only 19 out of 749 (2.5%) neonates
born to mothers with CHIKV infection became infected with CHIKV (Gerardin et
al., 2008a). CHIKV infected neonates have a high rate of mortality. Symptoms in
neonates include fever, pain, rash and edema in the periphery (Ramful et al.,
2007).

2.5. Epidemiology and Emergence
CHIKV was first isolated from blood of febrile patients and mosquito
species in October 1952 during an epidemic affecting villages in the Makonde
Plateau in the Southern province of Tanzania (Robinson, 1955). For the next 50
years, CHIKV re-emerged in different parts of Africa and South-east Asia causing
minor outbreaks affecting people in the hundreds and thousands. It is estimated
that CHIKV may have been introduced from Africa to Asia 80 – 100 years ago
(Volk et al., 2010). Most outbreaks occurred between 1960s and 1980s and a
significant decrease in number of outbreaks was observed in the 1990s (Zeller et
al., 2016).
However, in 2004, CHIKV re-emerged from the coast of Kenya and
extensively spread to multiple islands of the Indian ocean, India and SoutheastAsia affecting millions of people. Initially, 13,500 cases were reported in Lamu
island of Kenya, which comprised 70% of the island population. The epidemic
spread to the most notable La Reunion island, where 260,000 people were
affected (35% of the island’s population).
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During the La Reunion outbreak CHIKV was associated with an atypical
vector, A. albopictus. Previously, A. aegypti was known to be the classical vector
for CHIKV. After genomic analysis of strains obtained from outbreaks along the
Indian Ocean, a single amino acid mutation in the E1 glycoprotein, Ala226Val,
was identified. This mutation improved the ability of the virus to infect insect cells
by removing the need for cholesterol in the target membrane for entry (Gibbons
et al., 2003). As a result, it enabled the La Reunion CHIKV strain to utilize A.
albopictus as a new host. The transmission of CHIKV by A. albopictus results in
a more efficient transmission of CHIKV, as this mosquito species has a flight
radius of 400-600 m (A. aegypti females generally fly 100-500 m) and can
survive both rural and urban environments. It also feeds on various animal
species as well as humans and its eggs are viable through the dry season (Alto
and Juliano, 2001). Furthermore, the mosquito is more prevalent in the US and
European countries where the typical vector (A. aegypti) isn’t present.
From 2005 – 2006, CHIKV reemerged in India, after being inactive for 32
years, with more than 1.3 million cases reported (Zeller et al., 2016). In 2007, the
virus further spread to Europe during a small outbreak in Northeast Italy, where
217 cases occurred. In 2010, a limited outbreak was also documented in
southern France (Gould et al., 2010).
CHIKV has also emerged in the Americas. It was first identified in October
2013 on the island of St. Martin in the Caribbean (Cassadou et al., 2014). The
virus quickly spread to other Caribbean islands, as well as central, north and
south American countries owing to intense travel and presence of competent

16

Table 2
The yearly number of cases of CHIKV reported in the Americas (2013 – 2016).
2013

2014

2015

2016

Total (2013-2016)

111

1,147,515

726,478

114,199

1,988,303

vectors in the regions. As a result, the Pan American Health Organization
reported close to 1.2 million autochthonous cases in the Americas between 2013
and 2014. The CHIKV strain that emerged in the Americas was later found to be
of Asian origin and was unrelated to the better adapted virus that emerged in
India and Europe in preceding years (Gay et al., 2016). According to Rodriguez
et al., between 2015 – 2016, 840,677 cases of CHIKV were reported in the
Americas. The yearly number of reported cases of CHIKV in the Americas
between 2013 and 2016 is summarized in Table 2 (Rodriguez-Morales et al.,
2016). The yearly number of reported cases of CHIKV in the Americas between
2013 and 2016, as reported by Rodiguez-Morales et al, is summarized in Table
2. Although the number of CHIKV cases may have gone down, there is still the
risk that the virus might become endemic to new regions and cause future
outbreaks. Currently, CHIKV is present in 80 countries (Pietromonaco and
Powers, 2015).

2.6. Clades/Phylogenetic Groups
The various strains of CHIKV are categorized into three distinct
phylogenetic groups or clades namely, West African, East-Central-South African
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(ECSA), and Asian (Mohan et al., 2010). Phylogenetic analysis for classification
was primarily based on complete ORF and partial NS4 and E1 sequences of the
virus strains.
The three phylogenetic groups are estimated to have evolved from a
common ancestor in Africa 500 years ago. Despite their geographical proximity,
genetic lineages of ECSA and West African strains don’t closely overlap (Volk et
al., 2010). Therefore, it is difficult to distinguish where in Africa CHIKV first
emerged. The cause of divergence between the two African clades has yet to be
investigated. Evolution of CHIKV strains is mainly driven by nucleotide
substitutions that occur predominantly during the urban transmission cycle of the
virus in contrast to the sylvatic cycle (Volk et al., 2010).
Diversity among the clades includes differences in genome length. ECSA
(11,557 – 11,789nt) strains are found to be shorter than West African (11,843 to
11,881) and Asian clade viruses (11,777 to 11,999) (Volk et al., 2010). ORFs are
highly conserved among the clades, however; 5’ and 3’ untranslated regions
(UTRs) and 26S junctions were highly variable. There is a poly A tail insertion in
the 3’ UTRs of ECSA strains. Although, Volk et al (2010) have found the same
insertion in the genome of the Senegal, West African, strain. The clades also
differ in nucleotide substitution rates. The Asian lineage has shown the highest
mean rate of 4.16 X 10-4 nucleotide substitutions per site per year (subs/nt/yr),
while ECSA and West African strains exhibit rates of 2.3 x 10-4 and 2.39 x 10-4
subs/nt/yr, respectively (Volk et al., 2010).

18

2.7. Animal Models of Infection
Animal models utilized to investigate CHIKV infection include zebrafish,
mouse strains (including AG129, C57BL/6, DBA/1J, RAG -/-), Golden Syrian
hamsters and primates. Each of these models replicates some aspect of disease,
but none fully reproduce human disease completely.
Zebrafish have been used to study host-pathogen interactions during
CHIKV infection. Although they are the furthest removed model from humans,
they allow for ease of use of imaging and genetic techniques which are
instrumental in monitoring viral immune response. In zebrafish larvae infected
with CHIKV, upregulation of IFN-stimulated genes (ISGs) was observed. This is
consistent with antiviral signaling that occurs in humans and indicated that INFs
were orthologous genes that were highly conserved across vertebrates (Briolat et
al., 2014).
Adult wild type C57BL/6 mice have been infected with serially passaged
CHIKV to demonstrate rheumatic symptoms and virus titers in spleen, lymph
nodes, liver and muscles (Gardner et al., 2010). Footpad swelling peaked
between days 6 to 8 post infection. Persistent infection was detected 14 – 21
days post infection where virus was found in mononuclear cell infiltrates in
subcutaneous and connective tissues of infected feet (Gardner et al., 2010). Less
than 12 day old neonatal C57BL/6 mice exhibit severe disease and age
dependent lethality (Couderc et al., 2008).
Infection of AG129 mice, lacking type I and II interferon receptors, results
in a lethal disease phenotype. These mice are highly susceptible to infection and
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die rapidly. However, they provide a highly sensitive challenge model for
evaluating the efficacy of antiviral agents and vaccines (Haese et al., 2016). This
model also demonstrates the importance of the host interferon response to viral
control.
RAG1-/- mice lack the recombination activating gene 1 and are deficient in
T and B lymphocytes (Seymour et al., 2015). Use of the RAG-/- mouse model
has provided a better understanding of the role of the adaptive immune system in
CHIKV infection (Hawman et al., 2013). This model can be used to study chronic
CHIKV infection to understand the mechanisms that lead to prolonged arthralgia
and to evaluate vaccine safety.
In the DBA/1J mouse model, clinical signs observed in humans including
joint swelling, arthralgia, high virus titers and increased cytokine levels are
observed (Dagley et al., 2014). This model is useful in studying pathogenesis of
arthritis and to evaluate the efficacy of antiviral compounds and vaccines.
Compared to the other CHIKV arthritis models, the DBA/1J model is more
sensitive to CHIKV infection and consistently exhibits robust foot pad swelling
across different strains (Dagley et al., 2014).
Golden Syrian hamsters are also susceptible to CHIKV infection and can
serve as a useful outbred model with an intact immune system. Inflammation and
lesions in skeletal muscle, tendon and fascia are observed in CHIKV-infected
hamsters (Bosco-Lauth et al., 2015). Clinical signs are typically not observed in
this model and viremia is cleared in 4 days. Hamsters make suitable models for
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CHIKV transmission studies as they develop high viremia titers above the
experimental mosquito infectivity threshold (Bosco-Lauth et al., 2015).
For pre-clinical assessment of antiviral therapies and vaccines,
nonhuman-primates (NHPs) serve as excellent models as they are genetically
and physiologically closest to humans. They are also natural reservoirs of
CHIKV. Symptoms including joint pain, fever and rash were observed in primates
infected with CHIKV (Higgs and Ziegler, 2010). Viremia peaks 2-3 days post
infection and CHIKV is detected in spleen, lymph nodes, liver, muscles, and
joints (Chen et al., 2010). Persistent CHIKV infection is best investigated in NHPs
as the virus has been collected in from spleen, liver, and muscle tissues 44 days
post infection in Cynomolgus macaques (Broeckel et al., 2015).

2.8. Antiviral Therapy and Vaccine Development
Currently there are no approved antiviral therapies or vaccines available
for CHIK. Patients suffering from CHIK have predominantly been treated to
partially alleviate their symptoms by the use of non-steroidal anti-inflammatory
drugs (NSAIDs) and nonsalicylate analgesics.
CHIK patients of the 2006 La Reunion outbreak experiencing chronic
arthritis were treated with Methotrexate (MTX), a NSAID mainly developed for
rheumatoid arthritis (RA) (Hoarau et al., 2010). There appeared to be some
benefit after treatment. However, the mechanism of MTX in treating viral induced
arthritis is not understood. Taylor et al (2013) also provide evidence against
using MTX to treat arthritis induced by alphaviruses as the drug caused early

21

onset of disease when used to treat Ross River virus in mice (Taylor et al.,
2013). Furthermore, serious gastrointestinal complications have been observed
in patients treated with MTX. Therefore, the use of MTX is currently controversial.
A nonsalicylate analgesic that has been used most for CHIKV treatment is
paracetamol. It has also been used by La Reunion patients as an analgesic.
Extensive use of the drug (>3g/day) resulted in severe liver disease in patients.
(Parashar and Cherian, 2014).
Aside from symptomatic treatments, there are also several direct acting
antiviral therapies that have shown activity against CHIKV in cell culture or in
animal models. These drugs act by inhibiting viral entry, protein synthesis and/or
genome replication.
Antivirals that interfere with viral entry, such as Chloroquine, Arbidol,
Epigallocatechin gallate, Phenothiazines, and Flavaglines, are active against
CHIKV in vitro (Abdelnabi et al., 2015). However, most of them have not been
evaluated in animal studies. Of the few examined in vivo, Chloroquine has been
found to be ineffective in macaques infected with CHIKV (Chopra et al., 2014).
Antiviral drugs that inhibit CHIKV protein synthesis include Small
interfering RNA (siRNA) sequences and cephalotaxine alkaloids such as
Harringtonine and Homoharringtonine (Abdelnabi et al., 2015). siRNAs that
target nsP1 and E2 genes of CHIKV result in more than 90% inhibition of CHIKV
reduction in vitro when administered up to 24 hours post infection. Use of
multiple siRNAs have lowered viral titers by 99.6%. However, because of the
instability and degradation of siRNAs, virus titer rebounds 72 hours post
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treatment (Dash et al., 2008). Harringtonine and its analog homoharringtonine,
interfere with host cell translation machinery to inhibit CHIKV replication (Kaur et
al., 2013). The 90% cytotoxic concentration of Harringtonine is 1 µM, and it has
an EC50 of 0.24 µM (Kaur et al., 2013). Both harringtonine and
homoharringtonine are specifically more efficacious against La Reunion CHIKV
strain, with the A226V mutation in the E1 glycoprotein, than CHIKV strains with
wildtype E1 sequences (Abdelnabi et al., 2015). The cause for the elevated
efficacy has yet to be examined.
Compounds that target CHIKV genome replication include ribavirin,
mycophenolic acid, suramin, 6-azauridine and favipiravir (T-705). Ribavirin, a
guanosine analogue with a broad-spectrum antiviral activity against flaviruses
acts by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme
that regulates the intracellular guanine nucleotide pool. (Leyssen et al., 2005). It
is efficacious against CHIKV (EC50 = 341μM) in vitro. It has also been evaluated
in mice in combination with doxycycline to significantly reduce viral titer (Rothan
et al., 2015). An even more potent inhibitor of IMPDH, mycophenolic acid, is also
efficacious against CHIKV in vitro (Abdelnabi et al., 2015). Suramin, an antiparasitic drug that has shown efficacy against CHIKV in vitro, inhibits viral
replication of CHIKV and other alphaviruses by interfering with RNA binding
enzymes such as viral polymerases and helicases (Albulescu et al., 2015). The
uridine analog, 6-azauridine, inhibits CHIKV replication by interfering with
orotidine monophosphate decarboxylase enzyme and depleting intracellular
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UTP-pools (Rada and Dragun, 1977). In vitro, 6-azauridine proved efficacious
against CHIKV at very low (0.8-1.6μM) concentrations (Briolant et al., 2004).
Favipiravir (T-705) is a pyrazinecarboxamide derivative with broad
spectrum activity against RNA viruses including influenza virus, Rift Valley fever
virus, West Nile virus, yellow fever virus, foot-and-mouth disease virus and other
flaviviruses, arenaviruses, bunyaviruses and alphaviruses (Julander et al. 2009;
Abdelnabi et al. 2015; Caroline et al. 2014; Scharton et al. 2014; Gowen et al.
2013; Furuta et al. 2013). T-705 inhibits viral RNA-dependent RNA polymerase
(RdRp) without interfering with host DNA and RNA synthesis (Furuta et al.,
2013). Although the mechanism by which it interferes with CHIKV replication is
not yet determined, suggested mechanisms include chain termination and
induction of lethal mutagenesis (Furuta et al., 2013).
Different types of CHIKV vaccines currently under evaluation include live
attenuated, inactivated, chimeric, recombinant subunit, DNA, adenoviral vector
and virus-like particle (VLP) vaccines. In 1986, Levitt et al, developed an
attenuated vaccine after serially passaging the CHIKV strain 15561 in MRC-5
cells. The vaccine successfully produced neutralizing antibody in mice and
rhesus monkeys providing protection against the parent virus (Levitt et al., 1986).
However, although the vaccine proved to be highly immunogenic, in a Phase II
clinical study, it caused mild temporary arthralgia (Bettadapura et al., 2013).
Other live attenuated vaccines have been constructed via large deletions in
nsP3, 6K and E2 CHIKV genes (Hallengard et al. 2014; Piper et al. 2013;
Gardner et al. 2014). The most advanced live attenuated vaccine, currently in
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Phase II clinical trials, is the TSI-GSD-218 (Thailand/1556) 2ΔE2 vaccine
(Smalley et al., 2016).
The development of chimeric virus vaccines involves combining genomes
of multiple viruses. Chimeric CHIKV vaccines created by combining genomes of
CHIKV and Venezuelan Equine Encephalitis (VEE) or Eastern Equine
Encephalitis (EEE) virus have been tested in mice and found to be immunogenic
(Wang et al., 2011). Alternatively, recombinant virus vaccines are made by
introducing a piece of the genome of one virus into another by using genome
recombinant technology. Recombinant, vesicular stomatitis and measles viruses
carrying structural (C, E1 and E2) CHIKV protein genes have generated
immunity that protected mice from lethal challenge (Chattopadhyay et al. 2013;
Brandler et al. 2013). The most recent recombinant vaccine utilizes a modified
vaccinia virus Ankara (MVA) strain. MVA is widely known to be safe as it has
been clinically used as a recombinant vaccine for other diseases (Volz and
Sutter, 2013). The vaccine has been shown to be immunogenic and protective in
mice (Garcia-Arriaza et al., 2014).
DNA vaccine development for CHIKV involves genetically engineering
cells to produce CHIKV antigens. A prominent CHIKV DNA vaccine, pMCE321,
is a single plasmid envelope-based DNA vaccine that expresses C, nsP2, E2 and
E1 CHIKV proteins. pMCE321 has successfully protected mice and rhesus
macaques from CHIKV challenge (Mallilankaraman et al., 2011). Adenovectors
modified to carry structural protein genes of CHIKV have also proven
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immunogenic and have protected mice from developing viremia and arthralgia
(Wang et al., 2011).
Lastly, virus-like particles (VLPs), have also been used in CHIKV vaccine
development. The leading VLP vaccine currently under investigation is produced
by transfecting human embryonic kidney (HEK) 293 cells with plasmid DNA
coding for C-E3-E2-6K-E1 CHIKV proteins. It has been efficacious in primates
against wild-type CHIKV (Akahata and Nabel, 2012) and has recently entered a
phase I clinical trials (Kramer et al., 2013).
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CHAPTER 3
IN VITRO COMPARISON OF CHIKUNGUNYA STRAINS IN REPLICATION
KINETICS AND RESPONSE TO T-705 TREATMENT

3.1. Introduction
Chikungunya (CHIK) is a disease mainly characterized by acute febrile
arthralgia. It is caused by Chikungunya virus (CHIKV), which is an alphavirus
belonging to the Togaviridae family. CHIKV was first discovered in 1952 in
Tanzania. The virus reemerged in 2004, causing outbreaks in Africa, Asia and
territories on the Indian Ocean, resulting in millions of disease cases in these
regions. Virus outbreaks also occurred in Europe in 2007. In 2013, the virus was
introduced to the Caribbean, further spreading to countries in North and South
America. According to the Pan American Health Organization (PAHO), close to
1.2 million people were affected with CHIKV in the Americas in its first year of
expansion alone.
Currently there is no FDA-approved antiviral treatment or vaccine
available for the treatment or prevention of CHIKV. However, T-705 (C5H4FN3O2
– 6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a purine analog, has been
identified as a potential candidate for the treatment of CHIKV (Delang et al.,
2014).
T-705, also known by the trade name Favipiravir, is an antiviral drug that
is effective against a diverse group of RNA viruses in vitro and in vivo. It is active
against influenza viruses, as well as arenaviruses, bunyaviruses, flaviviruses,
alphaviruses, picornaviruses and noroviruses (Furuta et al., 2013). It is approved
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for the treatment of influenza in Japan, and is currently going through phase III
clinical trials in the US. T-705 has also been shown to be efficacious against
Chikungunya virus (Ahola et al., 2015).
The mechanisms of action of T-705 include inhibition of viral replication by
interfering with viral RNA dependent RNA polymerase and introduction of lethal
mutagenesis (Baranovich et al., 2014; Baranovich et al., 2013; Furuta et al.,
2005).
T-705 acts as a pseudo-purine. The structure of T-705 mimics that of
guanine and adenine nucleotides (Fig. 4). Furuta et al. and Mendenhall et al.
have shown that addition of excess purine nucleotides significantly reduces the
efficacy of T-705 against influenza virus and some arenaviruses (Arias et al.,
2014; Furuta et al., 2005; Mendenhall et al., 2011)
The antiviral activity of T-705 is dependent on its enzymatic intracellular
conversion to the ribofuranosyl-triphosphate species (T-705-RTP). According to a
pathway proposed by Furuta et al (2005), T-705 is converted to T-705
ribofuranosyl monophosphate (T-705-RMP) by the host enzyme Phosphoribosyltransferase. Nucleotide kinases further phosphorylate T-705-RMP into
ribofuranosyl-diphosphate (T-705-RDP) and ribofuranosyl-triphosphate (T-705RTP) derivatives (Fig. 5) (Furuta et al., 2005). T-705-RTP interferes with RdRp
by being incorporated in nascent viral RNA and partially preventing the extension
of the RNA strand (Furuta et al., 2013). Enzymatic kinetic analysis done by
Sandawe et al. has shown that T-705-RTP inhibited the incorporation of ATP and
GTP competitively (Sangawa et al., 2013).
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Fig. 5. The intracellular metabolism of T-705 into its active ribosylated,
triphosphorylated form (T-705-RTP)

It is unknown how T-705-RTP terminates chain elongation since it
contains a natural 3’ OH group. It is possible that the unnatural base may
contribute to chain termination by affecting the hydrogen bond of viral RNA bases
(Sangawa et al., 2013).
Another proposed antiviral mechanism of T-705 is lethal mutagenesis. T705 induces a high level of mutation that renders viral RNA non-viable. The
compound has been shown to elevate mutation frequency, increase the number
of G → A and C →T transversion mutations and result in shift of nucleotide
profiles in influenza A H1N1 viruses (Arias et al., 2014; Baranovich et al., 2013).
Time of addition studies have shown that T-705 has no antiviral effect
when added to virus adsorption and release stages. Early to intermediate stages
of viral replication are affected by the compound (Furuta et al., 2005).
Since RdRps are exclusive to RNA viruses and absent in human cells, T705 presents very minimal toxicity to the host. The effect of T-705-RTP against
human RNA and DNA polymerases as well as viral RdRp has been investigated.
T-705-RTP inhibited the RdRp of influenza virus at a minimal 50% effective
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concentration (EC50) of 0.341µM. However, the EC50 of T-705 against human
RNA polymerase II was 905µM and 50% inhibition against human DNA
polymerases (α, β or γ) was not observed as high as 1000µM (Kiso et al., 2010).
The specificity of T-705 in targeting viral polymerase without affecting host
polymerases makes it a very ideal antiviral compound.
In our lab, T-705 has shown variable efficacy against S27 and LR06
CHIKV strains in vivo (unpublished data). This presented the question whether T705 displayed differential efficacy against different strains of CHIKV in vitro. To
address this, four additional CHIKV strains, BVI, IND, SEN and NGR were
obtained, and tested for response to T-705 alongside S27 and LR06 strains.
To conduct T-705 antiviral testing, a study was first conducted to identify
suitable cell lines for in vitro assays. Previously in our laboratory, T-705 was
found to have limited efficacy against influenza in MA104 cells (unpublished
data). Variable EC50 values of T-705 against different arenaviruses and
bunyaviruses have also been observed (Gowen et al., 2007). The efficacy of T705 is largely dependent on cellular enzymes to metabolize it into its active
triphosphate form (Fig. 4), therefore the level of T-705 phosphorylation in various
cell lines was investigated.
Next, the replication kinetics of the S27 strain of CHIKV in different cell
lines was examined. After suitable cell lines for CHIKV replication were identified,
the replication kinetics of different CHIKV strains (BVI, IND, SEN, NGR, S27 and
LR06) were evaluated. Finally, comparative experiments were conducted to test
the response of the six CHIKV strains to T-705 treatment.
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3.2. Materials and Methods
3.2.1. Virus
The parental East African CHIKV isolate, S27 (VR-64), was obtained from
the American Type Culture Collection (ATCC) in Manassas, VA. La Reunion
Island (LR06 – LR2006-OPYI), Nigeria (NGR – IB H 35), Senegal (SEN –
37997), British Virgin Island (BVI, R 99659), and Indonesia (IND – RSU 1) strains
were obtained from Robert Tesh at the University of Texas Medical Branch
(UTMB). The S27, LR06, NGR, SEN, BVI and IND stock virus vials had virus
titers of 108.5 log10, 109 log10, 109.67 log10, 109 log10, 108 log10, and 108 log10 50%
cell culture infectious dose (CCID50)/1mL respectively. Virus stocks were
prepared by harvesting the supernatant from C6/36 cells that were grown in
RPMI at 28°C in 5% CO2 with 5% fetal bovine serum (FBS). Virus was diluted in
Minimal Essential Media (MEM) containing 2% fetal bovine serum (FBS) and
50mg/L gentamicin for in vitro testing.

3.2.2. Compound
T-705 was obtained from Toyama Chemical Company, Ltd. (Toyama,
Japan). The powder was dissolved in MEM containing 50μg/mL gentamicin
immediately prior to assays.

3.2.3. Cells
The cells utilized in this study included RD (Human – muscle –
rhabdomyosarcoma), Vero-76 (Primate – kidney epithelial), HEK 293 (Human –
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kidney epithelial), HEL 299 (Human – embryonic lung) and MA104 (Primate –
kidney epithelial) cells. They were obtained from ATCC and cultured in Eagle’s
medium with 10% FBS at 37°C and 5% CO2.

3.2.4. T-705 Phosphorylation and HPLC Analysis
Cell lines including Vero-76, HEK 293, HEL 299, RD and MA104 were
seeded in 25cm2 T-25 flasks in MEM containing 5% FBS. After 24 hours,
confluent flasks were treated with 100µM, 320µM and 1,000µM dilutions of T-705
in MEM containing 2% FBS and 50mg/L gentamicin. One flask was used for
each concentration of T-705 for each cell line. Control flasks were treated with
the same medium without T-705. The cell concentrations of the flasks ranged
between 4 x 106 – 6 x 106 of cells/mL at confluency. After a 24 hour incubation,
medium was aspirated and 540µL of 3.5% perchloric acid was added. After a 5
min refrigeration at 4°C, 270µL of 1N KOH/1 M imidazole solution was added to
neutralize lysate solution. After another 5 minute incubation at room temperature,
lysate was collected and stored in -80°C until HPLC analysis.
For HPLC analysis, a Waters 510 HPLC (Waters Corp., Milford, MA, USA)
fitted with a Kinetex 2.6µm (50X4.6mm) reverse phase C18 column
(Phenomenex Inc., Torrance, CA, USA) was used for the chromatographic
separation of T-705-RTP. A linear gradient of 0 to 5mM magnesium sulfate in
30mM TEA phosphate buffer (6.5 pH) was run for 30 minutes at 0.6mL/min. A
volume of 200µL of each sample was injected for analysis. Between sample
runs, the column was re-equilibrated with a 10 min wash with 60% acetonitrile. T-
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705-RTP eluted at ~18 min and was detected at a wave length of 360nm using a
Waters LC Spectrophotometer. The UV detector was set for 0.02 absorbance
units. A 10 µM T-705 standard was used to back calculate pmols of T-705-RTP
observed in samples. The number of cells in the untreated flasks containing each
cell line was determined using Countess II FL Automated Cell Counter
(ThermoFisher Scientific, Logan, UT) and used to calculate the concentration of
T-705-RTP/06 cells. Conversion of T-705 standard concentration to T-705-RTP
concentration was done by using the T-705:T-705-RTP ratio of 1:3.8 previously
specified by Smee et al. (2009).

3.2.5. Virus Replication Kinetics
Three replication kinetics experiments were conducted. The first was
conducted to measure the ability of CHIKV, specifically S27, to replicate in V-76,
HEK 293, HEL 299, RD and MA104 cell lines. The second was conducted to
quantify reduction of virus replication by T-705 in Vero-76 and MA104 cells. The
third was carried out to determine the abilities of the six CHIKV virus strains to
replicate in RD cells.
Both replication kinetics experiments were conducted using cells seeded
at a concentration of 4 x 104 cells/well on 96-well plates. Plates were infected
with the same 0.01 multiplicity of infection (MOI) or virion/cell. For the second
experiment, cells were treated with half log dilutions of T-705 starting at 1000µM.
Three separate experiments were conducted. In both experiments, 200µL of
supernatant from three wells were pooled for virus titration at 0, 6, 12, 18, 24, 30,
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26, 42, 48, 54, 60, 66, 72 hours post infection. Virus titers were assayed in 96well microplates infected with approximately 50 CCID50 per 0.1 ml and quantified
by the end-point dilution method (Reed and Muench, 1938).

3.2.6. T-705 In Vitro Antiviral Testing
Antiviral activity of T-705 was evaluated in the strains by cytopathic effect
(CPE) inhibition assay. 96-well plates, seeded at 4 x 104 cells/well, were infected
with each CHIKV strain. T-705 was diluted in half logs starting at 1,000µM in
MEM containing 2% FBS and gentamycin. Uninfected cells were also treated to
test cytotoxicity. Plates were incubated at 37°C and 5% CO2 until maximal viral
CPE was observed on day 3 and scored visually for CPE and toxicity.
Supernatants of wells containing virus were collected for virus yield reduction
assay.
Inhibition of virus replication was determined by microscopic evaluation of
infected cytopathic cells and quantified by neutral red (NR) uptake and virus yield
reduction assay. The 50% effective concentration (EC50) and the concentration
where 50% reduction in cell viability was observed (CC50) were calculated using
regression analysis. The selectivity index (SI) was obtained by dividing CC50 by
EC50. Virus yield reduction results were determined by the concentration of drug
that reduced the virus yield by 1 log10 unit (EC90) based on regression analysis.
First the efficacy of T-705 against the S27 strain was evaluated in multiple
cell lines. Next using a suitable cell line in which T-705 is active, antiviral efficacy
was evaluated against 6 (BVI, IND, S27, LR06, SEN and NGR) CHIKV strains.
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3.2.7. Statistical Analysis
Statistical analyses were done by two-way ANOVA using a Bonferroni
group comparison (Prism 7, GraphPad Software, Inc.).

3.3. Results
3.3.1. S27 CHIKV Strain Does Not Replicate Uniformly in Different Cell Lines
As can be seen in Figure 6, S27 did not replicate well in HEL 299 cells
although it displayed robust replication curves in V-76, HEK 293, RD and MA104
cells (Fig. 6). Virus titers obtained in Vero-76 cells between 18 – 72 hpi were
significantly (****P>0.0001 and ***P>0.001) higher than titers obtained in HEL
293 cells. The virus reached peak titers more rapidly in V-76 cells at 12 hours
post infection as compared with the other cell lines tested. Sufficient increase in
virus titers was observed in V-76, HEK 293, RD and MA104 cell lines, indicating
that these cell lines support suitable replication of CHIKV.

3.3.2. Replication of BVI, IND, S27, LR06, SEN and NGR CHIKV Strains in
Cell Culture
The NGR strain, closely followed by LR06 and SEN, produced high titers
throughout the incubation period compared to other strains (Fig. 7). The BVI and
IND strains replicated slower and produced significantly less virus between 12 –
42 HPI. The most significant (****P>0.0001) difference was observed between
the NGR and BVI CHIKV strains. Thus, these viruses were prime candidates for
comparison in in vivo experiments.
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Fig. 6. In vitro replication curves of S27 CHIKV strain in Vero-76, HEK 293,
HEL 299, RD and MA104 cell lines. (****P<0.0001, ***P<0.001; Virus titers of
Vero-76 cells compared to HEL 299 cells)
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Fig. 7. Comparison of growth curves of BVI, IND, S27, LR06, SEN and NGR
CHIKV strains in RD cells. (****P<0.0001, *P<0.05, Virus titers of NGR CHIKV
strain compared to the BVI CHIKV strain)
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3.3.3. Efficacy of T-705 Against CHIKV in Various Cell Lines
T-705 was effective (SI value >10) against CHIKV (S27) in Vero-76, HEK
293, HEL 299 and RD cells but was not efficacious in MA104 cells (Table 4).
Furthermore, virus reduction was measured in Vero-76 and MA104 cells treated
with half-log dilutions of T-705 up to 1,000µM. Concentrations between 32µg/ml
and 1,000µg/ml reduced virus titers in Vero-76 but not in Ma104 cells. At
1,000µM of T-705, cell viability is partially compromised, thus, the reduction
observed at that concentration in MA104 cells is not completely due to compound
efficacy. This raised the question whether the compound was effectively
metabolized into its active form in MA104 cells.

Table 3
Antiviral activity of T-705 against the S27 CHIKV strain in Vero-76, HEK 293,
HEL 299, RD and MA104 cells.
Cell Line

CC50a

EC50a

SI50

EC90a

SI90

Vero-76

260

7.5

34.9

6.1

43.1

HEK 293

150

6.8

22.1

4.16

36.1

HEL 299

280

6.7

41.8

16.0

17.5

RD

136

6.3

21.6

3.6

37.7

MA104

600

>600

0

>600

0

aCC ,
90

EC50, EC90 values are in µg/ml
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3.3.4. Phosphorylation of T-705 in Various Cell Lines
Using HPLC analysis, we demonstrated a dose dependent conversion of
T-705 to its active ribosylated-triphosphorylated form in HEK 293, HEL 299 and
Vero-76 cells (Fig. 8). However, T-705-RTP could not be detected in MA104 cells
treated with 1000µM, 320µM and 100µM of T-705. These data, together with the
antiviral inefficacy of T-705 in MA104 cells (Table 3), suggest that the lack of
activity in these cells is due to their inability to convert T-705 in to its active
phosphorylated form (T-705-RTP).

2000

6
T-705 RTP (pmol/10 cells)

1000µM
320µM
1500

100µM
0µM

1000

500

0

HEK 293

HEL 299

Vero-76

MA104

Cell lines

Fig. 8. Amount of T-705-RTP pmol/106 cells of HEK, HEL, V-76 and MA104
after being incubated for 24 Hrs with 1000µM, 320µM, 100µM and 0µM of T705.
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Fig. 9. HPLC Chromatogram of (A) 10µM of T-705 standard and lysates of
(B) HEK 293 and (C) MA104 cells treated with 320 µM of T-705. The active
ribosylated-triphosphorylated form of T-705, T-705-RTP was not detected in
Ma104 cells treated with T-705.

Table 4
Antiviral activity of T-705 against BVI, IND, S27, LR06, SEN and NGR strains of
CHIKV.

Clade
Asian
East/Central/
South African
West African

Virus Strain
British Virgin Islands (BVI)
Indonesia (IND)
Tanzania (S27)
La Reunion (LR06)
Senegal (SEN)
Nigeria (NGR)

T-705 (µM)
EC90 ± SDa
14.0 ± 7.8
16.0 ± 15.9
24.5 ± 6.8
27.0 ± 11.4
19.0 ± 14.8
33.0 ± 10.9

SI
85.7
75.0
48.9
44.4
63.1
36.3

a Data

are means and standard deviations from three separate experiments in
RD cells

3.3.5. T-705 is Efficacious Against BVI, IND, SEN, NGR, S27 and LR06
CHIKV Strains In Vitro
T-705 was active against all strains (SI value >10) and significant
difference in response to T-705 was not observed (Table 4). Difference in EC90
among the strains was not statistically significant. However, we do observe a
slightly higher EC90 average for the NGR strain compared to the Asian strains.
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3.4. Discussion
To identify a suitable cell line for use in measuring the efficacy of T-705
against CHIKV strains, replication kinetics of various cell lines were determined.
From these experiments, we identified that replication of CHIKV in HEL 299 cells
is less robust than Vero-76, HEK 293, RD and Ma104 cells. Efficient replication
of CHIKV is observed in various types of cells, including epithelial, endothelial
and fibroblast cells (Sourisseau et al., 2007). HEL299 cells are lung fibroblast
cells, therefore, it was unexpected to observe less robust CHIKV replication in
these cells.
Although CHIKV successfully replicated in MA104 cells, T-705 was found
to be non-efficacious in the cell line. We hypothesized that this was due to the
inability of MA104 cells to phosphorylate T-705, thus converting the compound
into its active form. We obtained preliminary data to support this hypothesis.
HPLC analysis revealed that MA104 cells treated with various concentrations of
T-705 did not produce T-705-RTP. Based on preliminary phosphorylation results,
as well as on CHIKV replication studies, Vero-76 and RD cells were selected for
use in antiviral studies in cell culture. Additionally, RD cells are a human muscle
cell line, thus representing a relevant cell type for investigating CHIKV.
There was some indication of a differential antiviral response among the
various clades of CHIKV in cell culture studies, although these differences were
not significant. T-705 appeared to be only slightly more efficacious against Asian
strains (BVI and IND) compared to ECSA (S27 and LR06) and West African
(SEN and NGR) clades. Thus, in vivo studies in mouse models were designed to
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further evaluate differences in antiviral response between different strains or
clades of CHIKV.
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CHAPTER 4
ANTIVIRAL EFFECT OF T-705 AGAINST DIFFERENT STRAINS OF CHIKV IN
AN ARTHRALGIA MOUSE MODEL

4.1. Introduction
Chikungunya virus (CHIKV), an alphavirus transmitted primarily by Aedes
mosquito species. Acute CHIKV infection with in 3 - 7 days post-infection is
characterized by fever, rash, joint swelling and debilitating polyarthritis. Within the
last decade the virus has affected millions of people around the globe (Handler et
al., 2017). Strains of CHIKV have currently been classified into three
phylogenetic groups/clades: West African, Asian and East/Central/South African
(ECSA).
Currently, there are no approved antiviral drugs or vaccines available for
CHIKV. Meanwhile, CHIKV continues to spread to different parts of the world
causing high morbidity in patients, and is expanding its geographical reach. As
with other RNA viruses, various adaptive mutations have been reported, which
have been important in increasing the range of the virus. Therefore, identifying
compounds with broad-spectrum activity against different CHIKV strains is
important.
T-705, an RNA-base analog with a broad activity against RNA viruses,
has been identified as a promising antiviral candidate for CHIKV in vitro and in
vivo (Ahola et al., 2015). However, the drug has been associated with different
levels of activity against two ECSA clade strains, S27 and LR06, in vivo. T-705
was active against the S27 strain, but not the LR06 strain, in a lethal mouse
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model (unpublished data). To further characterize the broad-spectrum activity of
T-705 against various strains of CHIKV, the following strains were obtained and
characterized in a mouse model of arthralgia: BVI and IND strains from the Asian
clade, and SEN and NGR strains of the West African clade.
To understand the phenotypic consequences of CHIKV strains, such as
rheumatic disease, and to evaluate differential response to antiviral treatment in
vivo, the arthralgia DBA/1J mouse model was utilized.
The DBA/1J mouse models various aspects of natural CHIKV infection,
including arthralgia and has been used for evaluating the efficacy of antiviral
candidates against CHIKV (Dagley and Julander, 2013). Infection of this mouse
strain with S27 (Dagley and Julander, 2013) or LR06 CHIKV results in significant
footpad swelling, similar to other models that have been described (Gerardin et
al., 2008b). Clinical symptoms, such as foot pad swelling, viremia and cytokine
levels can be reduced after treatment with an immune modulator (Dagley et al.,
2014). Herein, we describe the use of this mouse strain to identify phenotypic
differences between various clades of CHIKV and determine the effect of T-705
against selected strains at high and low treatment doses.

4.2. Materials and Methods
4.2.1. Animals
Seven to eight-week old female DBA/1J mice from Jackson Laboratories
were used after a quarantine period of 48 h. Animals were randomly assigned to
cages and individually marked with ear tags.
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4.2.2. Virus
Chikungunya virus isolates from British Virgin Islands (BVI, R99659 TVP
20811), Indonesia (IND, RSUI TVP-1336), Senegal (SEN, 37997 TVP-21089)
and Nigeria (NGR, IbH 35 TVP-1337) were obtained from Bob Tesh (WRCEVA).
The virus was passaged twice in C6/36 cells and virus stocks used in this study
had titers of 108, 109, 108 and 109.67 50% cell culture infectious doses
(CCID50)/ml, respectively.

4.2.3. Test Compound
T-705 was obtained from Toyama Chemical Company, Ltd. (Toyama,
Japan). The compound was dissolved in 2.9% sodium bicarbonate buffer (Life
Technologies, Carlsbad, CA). The T-705 dilution was filtered (0.2-micron filter)
for sterility and stored in amber glass injection bottles fitted with a metal cap.
Bottles were kept at 4ºC for the duration of the treatment schedule. The stability
of the compound in solution was confirmed using HPLC analysis for up to 10
days.

4.2.4. Experiment Design
4.2.4.1. Characterization of BVI, IND, NGR, SEN and LR06 CHIKV Strains in
DBA/1J Mice
Female DBA/1J mice were randomly assigned to groups of five animals.
The mice were weighed daily for six days starting from the day of infection (Day
0) and percent change in weight was calculated.
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Two characterization experiments were conducted. In the first experiment,
mice were infected with two challenge doses, 103.5 or 106.5 CCID50/0.1ml, of BVI,
IND and NGR CHIKV strains. Two different doses of each strain were used to
determine an effective infective dose that would result in foot pad swelling in
mice. In the second, the same study design was used and mice were infected
with the two challenge doses of BVI, NGR, SEN and LR06. A second
characterization experiment was conducted since unexpected results from the
first characterization experiment needed to be reaffirmed. Furthermore, it later
became apparent that including SEN and LR06 strains was necessary for
comparison. The viruses were prepared in minimal essential media (MEM).
Animals were anesthetized with isoflurane prior to subcutaneous (s.c.)
injection in the footpad and hock of the right leg with a total volume of 0.1 ml of
the diluted virus (0.05 ml each site). Animals were weighed and observed for
morbidity and mortality daily for the experimental duration of 9 days. Serum was
obtained via cheek bleeds on day 2 post infection to assess viremia. Footpad
measurements were obtained daily for 9 days using a caliper. Percent increase
in footpad swelling was assessed by comparing the right hind footpad, at the site
of virus challenge, to the contralateral left hind footpad (Dagley and Julander,
2013).
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4.2.4.2. Evaluation of the Efficacy of T-705 Against Robust CHIKV Strains in
DBA/1J
Mice were randomly assigned to groups of 10 animals. Two challenge
doses, 103.5 CCID50/0.1ml, of LR06, SEN and NGR strains were prepared in
minimal essential media (MEM). Animals were anesthetized with isoflurane prior
to subcutaneous (s.c.) injection in the footpad and hock of the right leg with a
total volume of 0.1 ml of the diluted virus (0.05 ml each site).
T-705 was dissolved in 2.9% sodium bicarbonate buffer (Life
Technologies, Carlsbad, CA) at a concentration of 38 mg/ml to deliver compound
at a treatment dose of 400 mg/kg/d. In a separate experiment, the compound
was dissolved in bicarbonate buffer at a concentration of 9.5 mg/ml in order to
treat animals with a 100 mg/kg/d treatment dose. The route of treatment
administration was via intraperitoneal (i.p.) injection. Mice were treated twice
daily for 8 days beginning 4h prior to virus challenge. A group of infected animals
was treated with a sodium bicarbonate vehicle along the same schedule as T705 and served as a placebo treatment control. Animals were weighed and
observed for morbidity and mortality daily for the experimental duration of 9 days.
Footpads were measured using a caliper every day for 9 days to check for foot
pad swelling. Percent increase in footpad swelling was measured as described
above. Serum was obtained through cheek bleeds on day 1 and 2 post infection
for titers. Five out of ten animals from both T-705 and vehicle groups were
necropsied on 6 dpi to obtain samples for virus and cytokine titration.
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4.2.5. Tissue Virus Titration
Right hind leg samples were weighed and homogenized in 1ml of MEM
containing 0.05 mg/ml gentamicin. The homogenates were centrifuged for 10 min
at 3,000 RPM. Serial log dilutions of the samples were plated in quadruplicate on
96-well plates seeded with Vero 76 cells. After an incubation period of 3 days at
37ºC and 5% CO2, the plates were examined for cytopathic effect (CPE) under
the microscope. Virus titers were determined by end point titration as described
previously (Reed and Muench, 1938).

4.2.6. Cytokine Analysis
Cytokines were quantified using the Q-Plex™ Mouse Cytokine – Screen
(16-Plex) kit (Quansys Biosciences in Logan, UT). The quantitative ELISA-based
chemiluminescent assay allows the concurrent measurement of the levels of 16
cytokines including, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17,
MCP-1, IFNγ, TNFα, MIP-1α, GM-CSF and RANTES. Cytokine levels in footpad
homogenates were quantified per manufacturer’s instructions. Briefly, samples
were diluted 1:5 and 1:25 in assay diluent, added to plates and read using a
Quansys Q-View TM Imager with Q-ViewTM software. Concentrations obtained
from the two dilutions were averaged during data analysis.

4.2.7. Statistical Analysis
Footpad swelling data were analyzed using two-way ANOVA. Statistical
analyses of weight, viremia and tissue virus titer were performed using one-way
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ANOVA using a Bonferroni group comparison (Prism 7, GraphPad Software,
Inc.).

4.2.8. Ethics Statement
This study was conducted in accordance with the approval of the
Institutional Animal Care and Use Committee of Utah State University dated
February 8, 2017 (Protocol #2713). The work was done in the AAALACaccredited Laboratory Animal Research Center of Utah State University.

4.3. Results
4.3.1. Characterization of Various CHIKV Strains in DBA/1J Mice
In the first characterization experiment, DBA/1J mice were infected with
103.5 CCID50 and 106.5 CCID50 of BVI, IND and NGR CHIKV strains. They were
weighed daily and measured for footpad swelling for 9 days. Serum was also
collected on the second day post infection for virus titer. No significant weight
changes were observed in the mice (Fig. 10).
Mice infected with a lower (103.5 CCID50) dose of the BVI strain had
detectable virus titer 2 days-post infection, while those infected with the higher
virus dose (106.5 CCID50) did not (Fig. 11). This was not completely unexpected,
as previous studies demonstrated earlier peaks in viremia in mice infected with
higher virus challenge (unpublished data). Mice that were infected with either of
the infective doses of the IND strain also did not have detectable viremia (Fig.
11). Thus, in a subsequent study, viremia was evaluated on day 1. Viremia was
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detectable in mice infected with

103.5

and

106.5

CCID50 challenge doses of NGR.

Despite a 1,000-fold difference in virus challenge dose, both NGR groups
resulted in serum virus titers that were not significantly different, demonstrating a
phenotypic difference between this strain with those of the Asian clade.
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Fig. 10. Mean percent weight change of DBA/1J mice infected with two
doses (103.5 CCID50 & 106.5 CCID50) of BVI, IND and NGR CHIKV strains.
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Fig. 11. Virus titer of serum collected 2 dpi from mice infected with two
doses (103.5 CCID50 & 106.5 CCID50) of BVI, IND and NGR.

Both Asian strains, BVI and IND, did not show significant footpad swelling
in DBA/1J mice (Fig. 12, A and B). This was not expected since the DBA/1J
mouse model has been identified as a useful model for replicating arthralgia
observed during natural infection after inoculation with various CHIKV strains
(Dagley et al., 2014).
The West African strain, NGR, caused significant footpad swelling on day
6 at the site of injection (Fig. 12C). Average swelling of the inoculated foot was
40% higher than the unchallenged contralateral foot (Fig. 12C, Table 5). There
was no significant difference in footpad swelling among the groups of mice
infected with two (103.5 and 106.5 CCID50) NGR challenge doses; indicating that
swelling may not be dose dependent in this strain. Contrarily, dose-dependent
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swelling has previously been observed in mice infected with the LR06 CHIKV
strain, as shown in preliminary data (Fig. 1).
Although insignificant in this experiment, some footpad swelling was also
observed on day 3 in mice infected with both challenge doses of NGR strain.
This bimodal joint swelling profile has been previously observed in both DBA/1J
(Fig. 1) and C57BL/6 mice infected with CHIKV (Gardner et al., 2010).
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Fig. 12. Percent change in footpad swelling of DBA/1J mice infected with
two doses (106.5 CCID50 and 103.5 CCID50) of (A) BVI, (B) SEN and (C) NGR
CHIKV strains.
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Table 5
Serum virus titers and percent increase in footpad swelling in DBA/1J mice
infected with two doses of BVI, IND and NGR.
Log10 serum
virus titera

Footpad swelling
(%) (n) b

106.5 CCID50

<0.7 ± 0.0

1.2 ± 3.7

103.5 CCID50

3.0 ± 0.6

4.5 ± 1.9

106.7 CCID50

<0.7 ± 0.0

4.5 ± 4.6

103.7 CCID50

<0.7 ± 0.0

2.7 ± 0.6

106.5 CCID50

3.7 ± 0.7

42.0 ± 4.4

103.5 CCID50

3.7 ± 0.7

45.5 ± 19.0

N/A

<0.7 ± 0.0

2.5 ± 10.0

Virus Dose

Strain
British Virgin Islands
(BVI)
Indonesia (IND)

Nigeria (NGR)
Sham

aSerum

was collected 2 dpi to determine virus titer.
increase in footpad as compared with the contralateral foot on 6 dpi.

bPercent

A second characterization study was conducted to compare disease
phenotype against a previously established LR06 strain, measure day 1 viremia
and confirm absence of footpad swelling in DBA/1J mice infected with BVI.
DBA/1J mice in this experiment were infected with BVI, LR06, NGR, and also
SEN. As expected no mortality or significant differences in weight change was
observed in mice infected with these CHIKV strains (Fig. 13).
Significant increase in serum virus titer was observed in the low challenge
dose groups on day 2 as compared with day 1 in mice that were infected with
BVI and SEN strains (Fig. 14). High challenge dose groups of the SEN and NGR
strain maintained relatively similar titers between day 1 and 2, while titers of high
challenge groups of BVI and NGR decreased on day 2. (Fig. 14)
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Fig. 13. Mean percent weight change of DBA/1J mice infected with two
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strains.
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Fig. 14. Virus titer of serum collected 1 (A) and 2 (B) dpi from mice infected
with two doses (106.5 and 103.5 CCID50) of BVI, SEN, NGR and LR06.
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Consistent with the previous characterization experiment, groups infected
with both challenge doses of BVI (CCID50 106.5 and 103.5), did not show
significant footpad swelling (Fig. 15A). This further suggests that the DBA/1J
mouse model may not be suitable for efficacy investigations involving Asian
strains. Although reduction of virus titer could be used to evaluate the efficacy of
antiviral agents. Overt arthralgia, however, could not be utilized in such studies.
The day of peak footpad swelling observed between groups infected with
two challenge doses of SEN strain (106.5 and 103.5 CCID50) differed from the
previous study (Fig. 15B). Delayed swelling was observed at in mice infected
with the lower challenge dose. While swelling in the high challenge dose group
peaked on day 6, the low dose group showed peak footpad swelling on day 7. A
similar phenomenon was observed in the groups infected with two different
infective doses of NGR (Fig. 15C). Nevertheless, the level of joint swelling in this
second experiment was consistent with the first (Fig. 12 and 15). DBA/1J mice
can be used to demonstrate swelling and viremia after infection with both SEN
and NGR, and thus can be used for evaluating antiviral compounds and vaccines
against those strains.
Mice infected with the higher dose of LR06 (106.5 CCID50) showed a peak
footpad swelling on day 6 (Fig. 15D), which is consistent with previous results
(Fig. 1). LR06 causes relatively more severe joint swelling in mice as compared
with other CHIKV strains. The 80% percent increase in swelling observed in the
mice that received the high challenge infection is also consistent with the
previous preliminary study (Fig. 1, Table 6).
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Fig. 15. Percent change in footpad swelling of DBA/1J mice infected with
106.5 and 103.5 CCID50 doses of (A) BVI, (B) SEN, (C) NGR and (D) LR06
CHIKV strains.
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Table 6
Serum virus titer and percent increase in footpad swelling in DBA/1J mice
infected with two doses of BVI, IND and NGR.
Log10 serum Log10 serum
Day 1 titer
Day 2 titer

Footpad swelling
(%) (n) a

Strain

Virus Dose

British Virgin
Islands (BVI)

106.5 CCID50

2.1 ± 0.8

1.1 ± 0.6

16.6 ± 9.9*

103.5 CCID50

<0.7 ± 0.0

2.2 ± 1.0

16.1 ± 4.8*

Senegal (SEN)

106.5 CCID50

3.1 ± 0.4

3.1 ± 0.4

46.9 ± 16.7¥

103.5 CCID50

1.5 ± 0.8

3.5 ± 0.7

48.0 ± 24.1*

106.5 CCID50

3.2 ± 1.5

2.8 ± 0.4

45.2 ± 8.9¥

103.5 CCID50

2.9 ± 0.9

3.6 ± 0.3

51.6 ± 30.2*

106.5 CCID50

4.2 ± 0.4

3.9 ± 0.4

84.0 ± 6.7¥

103.5 CCID50

<0.7 ± 0.0

1.0 ± 0.8

37.6 ± 7.5*

N/A

<0.7 ± 0.0

<0.7 ± 0.0

1.2 ± 2.8*

Nigeria (NGR)

La Reunion (LR06)

Sham

aPercent

increase in peak footpad swelling as compared with the contralateral
foot. Peak swelling was observed on 6 dpi¥ or 7 dpi*

4.3.2. Evaluation of the Efficacy of T-705 Against Various Strains in DBA/1J
Mice
The effect of T-705 was evaluated against strains that caused significant
swelling in DBA/1J mice. Consistent with characterization experiments, minimal
weight change and mortality was observed in DBA/1J mice infected with LR06,
SEN and NGR CHIKV strains and treated with 400mg/kg/d or 100mg/kg/d of T705 (Fig. 16).
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Fig. 16. Mean percent weight change of DBA/1J mice infected with LR06,
SEN and NGR CHIKV strains and treated with (A) 400mg/kg/d and (B)
100mg/kg/d of T-705.

Treatment with 400 mg/kg/d of T-705 significantly (****P<0.0001) reduced
viremia to baseline levels on day 2 (Fig. 17A). The virus titer reduction was
uniform across mice infected with all three CHIKV strains. Similar to the
400mg/kg/d dose of T-705, the 100mg/kg/d T-705 dosage also significantly
(****P<0.0001) reduced viremia in serum collected 2 days-post infection (Fig.
17B).
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The 400mg/kg/d T-705 treatment reduced virus titers at the site of
infection (right hind leg, RHL), but the reduction in virus titer varied from strain to
strain and was not reduced to baseline (Fig. 18A). Both treated groups of SEN
and NGR had an average RHL titer of 3.6 ± 1.1 and 3.3 ± 1.6, respectively (Table
7). These, and previous results, suggest that there is a phenotypic difference in
disease after inoculation of DBA/1J mice with West African clade viruses that is
more difficult to overcome as compared with strains from other clades. The low
T-705 dose did not result in the significant reduction of virus titers at the site of
infection (right hind leg) (Fig. 18B, Table 8), despite the significant reduction in
viremia reported above (Fig. 17B).
High dose treatment with T-705 was effective in significantly (****P<0.001)
reducing footpad swelling to baseline levels in mice infected with LR06, SEN and
NGR strains (Fig. 19). A dose of 100mg/kg/d of T-705, however, did not
significantly reduce footpad swelling in mice infected with these strains. As
shown in Figure 20, the low dose of T-705 treatment resulted in a delayed peak
in footpad swelling compared to mice treated with vehicle. Significant reduced
footpad swelling was only observed on day 6 in mice infected with LR06 and
NGR strains (Fig. 20 A and C).
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Fig. 17. Virus titer of serum collected on day 2 post-infection from mice
infected with LR06, SEN and NGR CHIKV strains and treated with (A)
400mg/kg/d and (B) 100mg/kg/d of T-705. (****P<0.0001, as compared to
vehicle treatment)
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Fig. 18. Virus titer of right-hind leg collected on day 6 post-infection from
mice infected with LR06, SEN and NGR CHIKV strains and treated with (A)
400mg/kg/d and (B) 100mg/kg/d of T-705 and vehicle. (***P<0.001; **P<0.01,
as compared to vehicle treatment)
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Fig. 19. Percent change in footpad swelling of DBA/1J mice infected with
SEN, NGR and LR06 CHIKV strains and treated with 400mg/kg/d of T-705.
(****P<0.0001, ***P<0.001; **P<0.01; *P<0.05, as compared to vehicle)
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Fig. 20. Percent change in footpad swelling of DBA/1J mice infected with
SEN, NGR and LR06 CHIKV strains and treated with 100mg/kg/d of T-705.
(****P<0.0001, **P<0.01, as compared to vehicle.)
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Of the 16 cytokines screened in right hind leg tissues collected on day 6,
only 4, MCP-1, RANTES, IFNγ and MIP-1α, were significantly increased with
CHIKV infection compared to controls. The other cytokines analyzed were not
significantly elevated in infected mice, compared with uninfected mice. MCP-1
and RANTES were significantly lowered by T-705 treatment in mice infected with
LR06, SEN and NGR strains (Fig. 21 A & C).
Levels of IFNγ and MIP-1α were not significantly elevated in mice infected
with the LR06 strain compared to uninfected control mice, but a trend toward
reduced cytokines in treated animals was observed. Mice infected with NGR also
did not show significant elevation of MIP-1α (Fig. 21D). However, mice infected
with the SEN strain showed significant increase in both IFNγ and MIP-1α
cytokines that were significantly reduced by T-705 treatment (Fig. 21 B & D).
Both MCP-1 and RANTES were significantly elevated in untreated mice
infected with SEN and NGR CHIKV strains, and subsequently reduced by
100mg/kg/d of T-705 treatment (Fig. 22). This treatment also resulted in reduced
IFNγ in mice infected with NGR and IFNγ and MIP-1α in mice infected with SEN.
Cytokine reduction profile of mice treated with 100mg/kg/d of T-705 is very
similar to mice treated with 400mg/kg/d of T-705 (Fig. 21 and 21).
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Fig. 21. The effect of 400mg/kg/d T-705 treatment on day 6 cytokine profile
of the hind leg of mice infected with 103.5 CCID50 of LR06, SEN and NGR.
(****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, as compared with vehicle
treatment).
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Fig. 22. The effect of 100mg/kg/d of T-705 treatment on cytokine profile of
the hind leg at the site of virus inoculation in CHIKV-infected mice on 6 dpi.
(****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, as compared with vehicle
treatment).
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Table 7
The effect of 400mg/kg/d dose treatment of T-705 on serum virus titer, right hind
leg virus titer and percent increase in footpad swelling in DBA/1J mice infected
with two doses of LR06, SEN and NGR.

Treatment

Strain

Log10 serum Day 2
titera ± SD

Log10 right hind leg
Day 6 titerb ± SD

Footpad swelling (%)c

T-705

LR06

<0.7 ± 0.0

2.2 ± 0.0

0.8 ± 2.0£

T-705

SEN

<0.7 ± 0.0

3.6 ± 1.1

-0.5 ± 1.3£

T-705

NGR

<0.7 ± 0.0

3.3 ± 1.6

-0.2 ± 2.7¥

Vehicle

LR06

3.2 ± 1.1

5.3 ± 1.0

44.4 ± 17.1£

Vehicle

SEN

4.1 ± 0.5

6.5 ± 1.1

39.1 ± 6.1£

Vehicle

NGR

4.2 ± 1.3

6.4 ± 0.9

45.5 ± 16.0¥

T-705

N/A

<0.7 ± 0.0

2.2 ± 0.0

-0.6 ± 1.8¥

Vehicle

N/A

<0.7 ± 0.0

2.1 ± 0.0

-1.1 ± 1.0¥

N/A

N/A

<0.7 ± 0.0

2.2 ± 0.0

0.3 ± 1.6¥

aSerum

collected 2 dpi to determine virus titer.
hind leg collected 6 dpi to determine virus titer.
cPercent increase in peak footpad swelling as compared with the contralateral
foot. Peak swelling was observed on 6 dpi¥ or 7 dpi£.
bRight
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Table 8
The effect of 100mg/kg/day of T-705 on serum virus titer, right hind leg virus titer
and percent increase in footpad swelling in DBA/1J mice infected with two doses
of LR06, SEN and NGR.

Treatment

Strain

Log10 serum Day 2
titera ± SD

Log10 right hind leg
Day 6 titerb ± SD

Footpad swelling (%)c

T-705

LR06

<0.7 ± 0.0

6.2 ± 0.4

34.7 ± 7.2

T-705

SEN

1.0 ± 0.4

4.8 ± 1.4

31.5 ± 9.5

T-705

NGR

0.8 ± 0.3

5.3 ± 0.8

37.9 ± 10.3

Vehicle

LR06

3.4 ± 0.9

6.6 ± 0.6

47.6 ± 14.6

Vehicle

SEN

4.3 ± 0.8

6.1 ± 0.5

32.7 ± 6.2

Vehicle

NGR

5.0 ± 0.4

6.4 ± 1.3

41.3 ± 9.8

T-705

N/A

<0.7 ± 0.0

2.1 ± 0.0

0.3 ± 2.1

Vehicle

N/A

<0.7 ± 0.0

2.1 ± 0.1

-0.7 ± 2.0

N/A

N/A

<0.7 ± 0.0

2.1 ± 0.1

0.4 ± 0.0

aSerum

collected 2 dpi to determine virus titer.
hind leg collected 6 dpi to determine virus titer.
cPercent increase in peak footpad swelling as compared with the contralateral
foot. Peak swelling was observed on 7 dpi
bRight

4.4. Discussion
The characterization of various CHIKV strains in DBA/1J mice
demonstrated that the strains display different levels of infectivity and disease
phenotype. Both Asian strains, BVI and IND, did not result in footpad swelling.
However, the West African strains, SEN and NGR, resulted in significant footpad
swelling with peak swelling observed on days 6 and 7 for 106.5 and 103.5 CCID50
challenge groups respectively (Fig. 12 and 15).
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Although mice infected with the Asian strains did not display footpad
swelling, the strains could potentially be passaged in mice in order to produce
adapted strains that might cause rheumatic disease. According to Gardner et al,
infection with an Asian strain from Thailand (isolate AF15561), resulted in
inconsistent viremia and resulted in no disease symptoms in C57BL/6 mice until
it was serially passaged in mice 9 times (Gardner et al., 2010).
Percentage increase in footpad swelling also varied among the strains.
The LR06 strain resulted in the highest 80% increase in footpad swelling, while
the NGR and SEN strains resulted in 40-50% increase. Footpad swelling was
dose dependent in mice infected with the LR06 strain, while mice infected with
SEN and NGR with two different challenge doses (106.5 CCID50 and 103.5 CCID50)
showed similar footpad swelling that weren’t significantly different. The day of
peak swelling was delayed in lower challenge dosage groups.
Since infection with BVI and NGR CHIKV did not result in footpad swelling
in DBA/1J mice, evaluation of T-705 efficacy against the two Asian strains was
not conducted in the DBA/1J mouse model. However, efficacy evaluation
experiments revealed that 400mg/kg/d of T-705 significantly reduced footpad
swelling and virus titers to baseline levels in mice infected with SEN, NGR and
LR06. Since these strains cause more robust disease and replicate at a more
rapid rate, it stands to reason that Asian clade strains would be effectively treated
with T-705. Treatment with this compound also reduced levels of proinflammatory cytokines, MCP-1, RANTES, IFNγ and MIP-1α. Footpad swelling is
caused by the infiltration of immune cells, primarily monocytes/macrophages, into
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infected synovial tissue and the accumulation of inflammatory cytokines (Gardner
et al., 2010). Thus, it was anticipated that the reduction of footpad swelling would
also have a concomitant decrease in cytokine levels.
Although treatment with 100mg/kg/d of T-705 reduced viremia and
cytokine levels in mice, it did not significantly reduce foot pad swelling or virus
titer in the right hind leg at the site of virus challenge. We find the observed
decrease in cytokine levels in the absence of decreased footpad swelling to be
contradictory. This may be due to the fact that cytokine levels were measured on
day 6 where we observe some reduction of footpad swelling due to T-705
treatment specifically for that day (Fig. 21). Low dose T-705 treatment did not
have any effect on virus titer at the site of infection. The right hind leg virus titers
of mice treated with 100mg/kg/d of T-705 were not different from mice treated
with the vehicle. Thus, there appeared to be a stronger correlation between
footpad swelling and virus titer in this study.
Virus titer reduction in the serum but not the right hind leg could be
explained by the fact that bio-distribution of T-705 to tissues is limited in mice
when the drug is administered in low concentrations. Synovial joints of infected
limbs in mice develop high virus titers. Although macrophages are critical in
clearing of virus from tissues, they are also important targets of CHIKV that carry
the virus at and towards site of infection. Infected macrophages harbored in
synovial joints have been implicated with causing chronic persistence of CHIKV
patients (Hoarau et al., 2010). Thus, if blood flow is compromised in arthritic
joints due to inflammation and increased synovial fluid, significant virus titer
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reduction in infected joints may require higher concentrations of antiviral
compounds (Haywood and Walsh, 2001).
In the DBA/1J model, difference in response to both treatment doses of T705 was not observed between the different strains of CHIKV. Footpad swelling
was uniformly reduced in mice infected with SEN, NGR and LR06 in the
400mg/kg/d of T-705 treatment experiment. 100mg/kg/d of T-705 also failed to
improve disease across all strains. The one parameter that suggested difference
in response to treatment was day 2 serum titer of mice treated with 100mg/kg/d
of T-705.
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CHAPTER 5
ANTIVIRAL EFFECT OF T-705 AGAINST DIFFERENT STRAINS OF CHIKV IN
A LETHAL MOUSE MODEL

5.1. Introduction
Chikungunya virus (CHIKV) is an alphavirus that causes Chikungunya
disease, which is mainly characterized by acute febrile arthralgia. The virus
emerged in 2004 and has since been spreading extensively throughout the
world. Within the last decade, it has caused a series of outbreaks resulting in
over 3.3 million cases (Powers, 2015). The various strains of CHIKV currently
found around the world have been grouped into three phylogenetic
groups/clades, namely, West African, Asian and East/Central/South African
(ECSA).
Currently, there are no approved antiviral drugs and vaccines available for
CHIKV. Therefore, identifying compounds that are efficacious against multiple
strains of CHIKV belonging to the different phylogenetic groups is critical.
Recently, T-705, a purine analog that has exhibited broad activity against
multiple RNA viruses has been identified as an ideal candidate for treating
CHIKV (Delang et al., 2014).
There are several different types of animal models utilized for evaluating
antiviral efficacy against CHIKV in vivo (Haese et al., 2016). Infection of AG129
mice, deficient in interferon α/β and γ receptors, results in lethal disease, as
these mice are highly susceptible to CHIKV (Couderc et al., 2008). As they lack a
critical antiviral immune response, they succumb to virus infection within 4 – 7

73

days. This also makes them useful to test effective therapeutics and vaccines as
well as for studying the role of type I IFN system in CHIKV pathogenesis.
Herein, we describe the disease phenotype of AG129 mice infected with
various strains of CHIKV belonging to different phylogenetic groups. The efficacy
of T-705 is then evaluated against certain strains of CHIKV to determine if there
is a difference in the efficacy of treatment against virus strains with differing
disease severity.

5.2. Materials and Methods
5.2.1. Animals
Male and female AG129 mice with an average weight of 22g were
obtained from an in-house breeding colony at the Institute for Antiviral Research.
The mice used were between 8 – 10 weeks of age. The mice were randomly
assigned to experimental groups and individually marked with ear tags. The mice
were weighed daily for six days starting from the day of infection (Day 0) and
percent change in weight was calculated.

5.2.2. Test Compound
T-705 was obtained from Toyama Chemical Company, Ltd. (Toyama,
Japan). T-705 was dissolved in 2.9% sodium bicarbonate buffer (Life
Technologies, Carlsbad, CA) at a concentration of 38 mg/ml to deliver compound
at a treatment dose of 400 mg/kg/d. In a separate experiment, the compound
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was dissolved in bicarbonate buffer at a concentration of 9.5 mg/ml in order to
treat animals with a 100 mg/kg/d treatment dose.

5.2.3. Virus and Cells
Chikungunya virus isolates from British Virgin Islands (BVI, R99659 TVP
20811), Nigeria (NGR, IbH 35 TVP-1337), Tanzania (S27) and Reunion Island
(LR06, LR2006-OPYI) were obtained from Robert Tesh (UTMB, WRCEVA).
Virus stocks were prepared by passaging twice in C6/36 cells. The passage 2 of
the BVI, NGR, S27 and LR06 virus stocks used had titers of 108, 109.67 and 108.5
and 109 50% cell cultures infectious doses (CCID50)/1ml, respectively. For
titration and plaque neutralization assays the African green monkey kidney cell
line, Vero 76, was used. The cell line was purchased from the American Type
Culture Collection (ATCC, Manassas, VA) and maintained in minimal essential
medium (MEM) containing 10% fetal bovine serum (FBS) (GE Healthcare
HyClone Laboratories, Logan, UT).

5.2.4. Viral Titer Assay
The virus titers in tissues or plasma were assayed using the end point
dilution assay where serial log dilutions of samples were made and added to
Vero 76 cells on 96-well plates. After three days of incubation, cytopathic effect
(CPE) was used to identify the end-point of infection. Four replicates were used
to calculate the 50% cell culture infectious doses (CCID50) per mL of plasma or
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gram of tissues. The assay had a lower limit of detection for virus at 0.7 log10
CCID50/mL serum.

5.2.5. CHIKV Plaque Reduction Neutralization (PRNT) Assay
PRNT50 assay was used to quantify antibody levels of serum as previously
described (Warter et al., 2011). Briefly, the assay was conducted using 12-well
plates seeded with 4 x 105 Vero-76 cells/mL. Serum samples were diluted 1:2
starting with a 1/10 dilution. To inactivate any virus present in the serum, the
samples were incubated for 30 minutes at 56°C. Equal volumes of diluted
CHIKV, titrated to produce a countable number of plaques, was added to the
sample dilutions. A resulting volume of 250 µL was added to a single well of a
12-well plate. The plates were incubated at 37°C and 5% CO2 for one hour to
allow for virus attachment, after which 1mL of 1.7% methylcellulose (4000 cps,
Sigma-Aldrich), overlay was added. Three days later, cells were stained by the
addition of crystal violet dye containing 10% formalin for 30 minutes. Plates were
then thoroughly washed and allowed to dry before plaques were counted. The
inverse of the dilution that caused a 50% reduction in plaque number was
reported as the plaque reduction neutralization titer.
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5.2.6. Experiment Design
5.2.6.1. Characterization of BVI, NGR and LR06 CHIKV Strains in AG129
Mice
AG129 mice of both genders were randomly assigned to cages of 4 - 5
animals per group. Two virus doses of 101.5 and 102.5 CCID50/0.1ml of BVI, NGR,
S27 and LR06 strains were prepared in MEM. The high virus challenge groups of
each strain contained five mice while each low challenge dose groups contained
four mice. Animals were anesthetized with isoflurane prior to subcutaneous (s.c.)
injection in the footpad and the hock of the right leg with a total inoculum volume
of 0.1 ml of the diluted virus (0.05 ml each site). Survival was monitored twice a
day for morbidity and mortality for the experimental period of 10 days. Weight
change was monitored from 0-5 dpi. Serum was obtained through cheek bleeds
on day 2 post infection for viral titers.
Serum was also obtained on day 14 after the course of the experiment via
cheek bleeds for a Plaque Reduction Neutralization Test (PRNT). This was done
to confirm that effective infections were administered in the mice that survived at
the end of the experiment.

5.2.6.2. Evaluation of the Efficacy of T-705 Against SEN, NGR and LR06
CHIKV Strains
Male and female AG129 mice were randomly assigned to cages of seven
animals per group. 102.5 CCID50/0.1ml of BVI, NGR, S27 and LR06 CHIKV
strains were prepared in MEM.
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Treatment with a dose of 400 mg/kg/d of T-705 began four hours prior to
virus infection and was administered twice a day for six days via intraperitoneal
(i.p.) injection. Animals were anesthetized with isoflurane prior to subcutaneous
(s.c.) injection in the footpad and the hock of the right leg with a total inoculum
volume of 0.1 ml of the diluted virus (0.05 ml each site).
Survival was monitored twice a day for morbidity and mortality for the
experimental period of 10 days. Weight change was monitored from 0-5 dpi.
Serum was obtained through cheek bleeds on day 2 post infection for viral titers.

5.2.7. Statistical Analysis
The Wilcoxon log-rank test was used to analyze the survival data of mice.
Statistical analyses of weight, tissue virus and antibody titer were performed
using one-way ANOVA using a Bonferroni group comparison (Prism 7,
GraphPad Software, Inc).

5.2.8 Ethics Statement
This study was conducted in accordance with the approval of the
Institutional Animal Care and Use Committee of Utah State University dated
February 8, 2017 (Protocol #2713). The work was done in the AAALACaccredited Laboratory Animal Research Center of Utah State University.
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5.3. Results
5.3.1. Characterization of Various CHIKV Strains in AG129 Mice
To characterize the disease phenotype of different strains of CHIKV
belonging to the three clades in a lethal model, AG129 mice were inoculated with
BVI, NGR, and LR06 strains. Survival, weight change and viremia were
determined.
Weight change observed over the course of the study was minimal (less
than 6%) (Fig. 23). The uniform decline within the first two days can be likely
attributed to excessive handling due to infection and beginning of treatment
regimens. There was no significant difference between mice infected with two
different challenge doses of each strain. Weight decreased sharply in mice
infected with BVI just prior to death (Fig. 23). Less weight change was observed
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Fig. 23. Mean percent weight change of DBA/1J mice infected with two
doses (101.5 and 102.5 CCID50) of BVI, NGR and LR06 CHIKV strains.
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after infection with NGR, as these mice succumbed to virus infection very early in
the study. There was a dose-dependent increase in viremia observed in AG129
mice infected with BVI and LR06 CHIKV (Fig. 24). Higher dose challenge
resulted in a significantly higher serum titer. Virus titers for the high (10 2.5 CCID50)
NGR challenge group are not shown because the mice died on the day of serum
collection. Serum titers measured in mice infected with BVI or LR06 were not
significantly different from each other. However, the titer of the low dose
challenge group of mice infected with NGR was significantly (P<0.0001) higher
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than the mice infected with either (102.5 or 102.5) doses of BVI and LR06 strains.

Fig. 24. Virus titer of serum collected 2 dpi from mice infected with two
doses (101.5 and 102.5 CCID50) of BVI and LR06, and mice infected with 1.5
CCID50 NGR. (**P<0.01; *P<0.05, as compared to vehicle treatment)
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Although DBA/1J mice did not show observable clinical signs of disease
when infected with Asian strains (BVI or IND), AG129 mice succumbed to
disease after infection with BVI (Fig. 25A). This demonstrates the utility of this
mouse strain to evaluate antiviral compounds against Asian strains. The BVI
strain was the least robust strain tested in this study with the latest mean day-todeath (Fig. 25, Table 9). As can be seen in Figure 25, 75% (3 out of 4) of the
mice infected with the low LR06 challenge dose survived infection. The three
mice that survived were the same mice that also did not show detectable serum
virus titer on day 2 (Fig. 24). It is most likely that the mice did not receive a
sufficient virus challenge to cause a lethal infection.
The high serum virus titer combined with early average mean day-todeath observed in mice infected with NGR suggest that this strain is significantly
more robust than BVI and LR06 (Fig. 25, Table 9).
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Fig. 25. Survival of AG129 mice challenged with 101.5 and 102.5 CCID50 doses
of (A) BVI, (B) NGR and (C) LR06 CHIKV strains.
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Table 9
Serum titer & mortality of AG129 mice infected with BVI, NGR, and LR06 CHIKV
strains.
Infective
Log10 serum
CCID50 virus titera ± SD

Strain

Survival
(alive/total)

Mean day-to-death
± SD

British Virgin
Islands (BVI)

101.5

2.0 ± 1.6

0/4

5.5 ± 0.6

102.5

5.1 ± 1.1

0/5

4.4 ± 0.6

Nigeria (NGR)

101.5

9.2 ± 0.6

0/4

3.0 ± 0.0

102.5

N/A

0/5

2.2 ± 0.5

La Reunion
(LR06)

101.5

5.3

3/4

4.0

102.5

6.0 ± 1.2

0/5

3.8 ± 0.5

Sham

N/A

<0.7 ± 0.0

3/3

>10.0 ± 0.0

aSerum

was collected 2 dpi to determine virus titer.

5.3.2. Evaluation of the Efficacy of T-705 Against Selected CHIKV Strains in
the AG129 Mouse Model
Unlike the characterization study, to evaluate differences in response to T705 treatment, LR06 was substituted with the S27 strain. Since T-705 was
effective in the treatment of the S27 strain in a preliminary study (unpublished
data), while treatment of LR06 was not effective, we selected the S27 strain for
use as a positive control in this study.
Minimal weight change was observed on most days in mice infected with
S27, BVI and NGR CHIKV strains and treated with 400 mg/kg/d of T-705 (Fig.
27). However, untreated mice infected with the S27 strain failed to gain weight on
day 2 compared to the other mice in the experiment.
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Fig. 26. Mean percent weight change of AG129 mice infected with 102.5
CCID50 of BVI, NGR and LR06 CHIKV strains and treated with 400 mg/kg/d
of T-705. (****P<0.0001, vehicle compared to T-705 treatment)
Treatment with T-705 significantly (P<0.001) lowered virus titers in mice
infected with all three strains as compared with untreated mice (Fig. 27). There
was a fairly uniform decrease in viremia, with a decrease in titer around 10 6
CCID50. NGR still proves to be the most robust strain, as mice infected with the
strain and treated with T-705 still showed the highest average virus titer 3.4 log10
CCID50 (Fig. 27, Table 10). Mice infected with BVI and treated with T-705 had
viremia reduced to the low level of detection, with the lowest average virus titer of
0.8 log10 CCID50 (Table 10).
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Fig. 27. Virus titer of serum collected 2 dpi from mice infected with S27, BVI
and NGR CHIKV strains and treated with 400 mg/kg/d of T-705.
(****P<0.0001, as compared to vehicle treatment)

Antiviral treatment with T-705 significantly improved survival in mice
infected with BVI and S27 strains but not with the NGR strain (Fig. 28). There
was no statistical difference between survival data of treated and untreated mice
infected with NGR. In groups of mice infected with S27 and BVI and treated with
T-705, 4/8 and 5/8 mice survived, respectively (Table 10). However, all treated
mice infected with the NGR strain succumbed to disease.
To confirm that the survival of mice in the study was due to T-705
treatment after successful infection with CHIKV, a Plaque Reduction
Neutralization Test (PRNT) was conducted using serum acquired from the mice
at day 14 post infection.
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Fig. 28. Survival of AG129 mice challenged with (A) S27, (B) BVI and (C)
NGR CHIKV strains and treated with 400 mg/kg/d of T-705. (***P<0.001 as
compared to vehicle treatment).
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Levels of neutralizing antibody present in mice treated with T-705 that
survived S27 and BVI infections were 104.1 and 103.5 PRNT50, respectively (Fig.
29). In addition to day 2 serum titers, this confirms the infection of the mice with
S27 and BVI CHIKV strains and that successful immune response was
established.
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Fig. 29. Neutralizing antibody in mice treated with 400 mg/kg/d of T-705 and
infected with S27 and BVI CHIKV strains. (****P<0.0001, as compared with
sham infection).
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Table 10
Serum titer & mortality of AG129 mice infected with S27, BVI and NGR CHIKV
strains.
Survival
(alive/total)

Mean day-todeath ± SD

2.1 ± 2.0

4/8

6.0 ± 2.7

BVI

0.8 ± 0.5

5/8

7.3 ± 2.3

T-705

NGR

3.4 ± 2.0

0/8

4.3 ± 1.2

Vehicle

S27

7.9 ± 1.4

0/8

3.1 ± 0.4

Vehicle

BVI

5.4 ± 0.8

0/8

4.1 ± 0.4

Vehicle

NGR

8.5 ± 0.0

0/8

2.9 ± 0.4

N/A

N/A

0.7 ± 0.0

3/3

>14.0 ± 0.0

Treatment

Strain

T-705

S27

T-705

aSerum

Log10 serum virus
titera ± SD

was collected 2 dpi to determine virus titer.

5.4. Discussion
T-705 is an antiviral candidate that has broad activity against a wide range
of RNA viruses. It has been tested in previous studies against the S27 and LR06
strains (Ahola et al., 2015). In the present study, the efficacy of T-705 was
evaluated against three CHIKV strains belonging to different phylogenetic clades
in the lethal AG129 mouse model.
T-705 significantly reduced viremia in AG129 mice that were infected with
BVI, NGR and S27 CHIKV strains. T-705 also significantly improved survival of
mice infected with the BVI and S27 strains. However, the most interesting finding
in this study was that T-705 failed to significantly improve survival of mice
infected with the West African strain, NGR. The NGR strain also replicated in the
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AG129 mice more rapidly resulting in higher viremia compared to BVI and S27.
This complements higher replication kinetics observed in in vitro experiments,
establishing the strain’s robustness.
Genetic contributions to phenotypic robustness observed after infection
with the NGR strain have yet to be determined. Genetic mutations have been
shown to be associated with increasing CHIKV virulence. The LR06 strain is
associated with an E1: V226A mutation that allowed it to adopt to a new
mosquito vector, A. albopictus, with a greater geographical range of infection
than the original vector, A. aegypti (Tsetsarkin et al., 2007). Recently, Agarwal et
al (2016), have identified two more mutations other than the E1: V266A mutation
that also increase LR06 infectivity (Agarwal et al., 2016). The two mutations,
E1:K211E and E2:V264A, are reported to increase infectivity, dissemination and
transmission of CHIKV by 13, 15 and 16 folds, respectively (Agarwal et al.,
2016).
Infection with the NGR strain of CHIKV resulted in a rapidly lethal and
robust infection, although it is currently unknown if any genetic sequences
contribute to this disease phenotype. A mutation that results in an amino acid
difference has already been described in the BVI strain. The BVI strain has a
mutation at the E2:113 position where the original valine amino acid is changed
to an alanine (Lanciotti and Lambert, 2016). Although this mutation in the
structural E2 protein could provide potential advantages in cell tropism and
infectivity, according to our experiments, these mutations in the BVI strain do not
appear to provide an enhanced disease phenotype in the AG129 mouse model.
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In fact, BVI has been shown to be weaker than the other strains we investigated.
In our experiments, T-705 treatment reduced viremia in AG129 mice infected
with BVI to almost baseline levels. Mice infected with BVI also had the latest
mean-day-to-death. In comparison, the NGR strain did not respond to T-705
treatment and resulted in lethality of all treated mice with the earliest mean-todeath.
Therefore, in the more stringent AG129 animal model, differences in
disease phenotype and response to T-705 can be observed among the different
strains of Chikungunya. Although CHIKV does not cause death in human clinical
cases, the AG129 model can be a useful tool in evaluating potential drugs
against various strains of CHIKV to establish global efficacy.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

Chikungunya virus has become a major public health concern since its
reemergence in 2004 (Handler et al., 2017). Since there are no approved
antiviral drugs or vaccines to treat or prevent CHIKV, it is of critical importance to
identify potential candidates that can be used against the virus. T-705 has
previously shown efficacy against CHIKV (Delang et al., 2014). Therefore, it is
important to evaluate its range of efficacy against various strains of the virus.
In our studies, the responses of BVI, IND, SEN, NGR, S27 and LR06
CHIKV strains to T-705 treatment were investigated in vitro and in vivo. Our
results in cell culture indicated that T-705 had some slight differences in efficacy,
with a pattern towards greater efficacy against Asian lineage CHIKV strains. The
strains also displayed slight differences in replication curves in RD cells.
Similarly, mice infected with different strains of CHIKV exhibited different
disease phenotypes. DBA/1J mice infected with LR06 CHIKV showed an
approximately 80% increase in footpad swelling. Mice infected with the S27,
NGR and SEN strains showed 40 - 50% increase in footpad swelling. Both LR06
and S27 are grouped under the ECSA clade, while NGR and SEN belong to the
West African clade. The two Asian clades, BVI and IND, did not cause significant
measurable foot pad swelling in DBA/1J mice, demonstrating a difference
between clades in regard to disease phenotype. Infection with another Asian
strain from Thailand (isolate AF15561) also failed to cause footpad swelling in
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C57BL/6 mice, even after adaption of the virus by passaging it nine times in mice
(Gardner et al., 2010), further confirming our work in DBA/1J mice.
A similar differential response to T-705 treatment was observed in vivo. In
the DBA/1J model, 400mg/kg/d of T-705 uniformly reduced footpad swelling in
mice infected with NGR, SEN and LR06. Treatment with 100 mg/kg/d of T-705
reduced footpad swelling, significantly in mice infected with LR06 and SEN, on
day 6, but footpad swelling increased thereafter in treated mice. Interestingly,
viremia was reduced to baseline levels in mice infected with LR06 and treated
with 100mg/kg/d of T-705, but not in mice infected with NGR and SEN despite
significant reductions.
In a lethal model of CHIKV infection in AG129 mice, treatment with T-705
(400mg/kg/d) improved survival in mice infected with BVI and S27 strains, but
failed to improve survival in mice infected with NGR. Since NGR and SEN
showed similar disease profiles in DBA/1J mice, it would be likely that T-705
would also have no effect on the survival of AG129 mice infected with SEN. This
should be investigated in future studies.
Finally, an important step forward to understanding differences in disease
phenotype and response to antiviral treatment among CHIKV strains would be to
conduct genotypic analysis. Previously, mutations in CHIKV have been
associated with increased infectivity and adaption to a new vector (Agarwal et al.,
2016). However, the effect of mutations in causing differential response to
antiviral treatment needs to be researched and further investigated.
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